

Number	Publication	Protocol Number	PMCID
2004			
1	Wingard JR. Design issues in a prospective randomized double-blinded trial of prophylaxis with fluconazole versus voriconazole after allogeneic hematopoietic cell transplantation. Clinical Infectious Disease. 2004 Oct 15; 39 Suppl 4:S176-180. doi: 10.1086/421953.	BMT CTN 0101	N/A (pre-dates PMCID requirements)
2005			
2	Logan BR. Optimal two-stage randomized Phase II clinical trials. Clinical Trials. 2005 Feb 1; 2(1):5-12. doi: 10.1191/1740774505cn061oa.	BMT CTN 0302	N/A (pre-dates PMCID requirements)
3	Ho VT, Cutler C, Carter S, Martin P, Adams R, Horowitz M, Ferrara J, Soiffer R, Giralt S. Blood and Marrow Transplant Clinical Trials Network Toxicity Committee consensus summary: Thrombotic microangiopathy after hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2005 Aug 1; 11(8):571-575. doi: 10.1016/j.bbmt.2005.06.001.	Network publication	N/A (pre-dates PMCID requirements)
2007			
4	Keating A. Editorial: Prospective clinical trials in BMT come of age in the US: The Blood and Marrow Transplant Clinical Trials Network. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2007 Mar 1; 13(3):255-256. doi: 10.1016/j.bbmt.2007.01.068	Network publication	N/A (pre-dates PMCID requirements)
5	Weisdorf D, Carter S, Confer D, Ferrara J, Horowitz M. Blood and Marrow Transplant Clinical Trials Network (BMT CTN): Addressing unanswered questions. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2007 Mar 1; 13(3):257-62; discussion 255-256. doi: 10.1016/j.bbmt.2006.11.017	Network publication	N/A (pre-dates PMCID requirements)
6	Ferrara J, Anasetti C, Stadtmauer E, Antin J, Wingard J, Lee SJ, Levine J, Schultz K, Appelbaum F, Negrin R, Giralt S, Bredeson C, Heslop H, Horowitz M. Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2007. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2007 Nov 1; 13(11):1268-1285. doi: 10.1016/j.bbmt.2007.08.005.	Network publication	N/A (pre-dates PMCID requirements)
2008			

Number	Publication	Protocol Number	PMCID
7	Cutler C, Stevenson K, Kim HT, Richardson P, Ho VT, Linden E, Revta C, Ebert R, Warren D, Choi S, Koreth J, Armand P, Alyea E, Carter S, Horowitz M, Antin JH, Soiffer R. Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. Blood. 2008 Dec 1; 112(12):4425-4431. doi: 10.1182/blood-2008-07-169342. Epub 2008 Sep 5.	BMT CTN 0402	PMC2597119
8	Logan B, Leifer E, Bredeson C, Horowitz M, Ewell M, Carter S, Geller N. Use of biological assignment in hematopoietic stem cell transplantation clinical trials. Clinical Trials. 2008 Dec 1; 5(6):607-616. doi: 10.1177/1740774508098326.	BMT CTN 0102	PMC2671015
2009			
9	Alousi A, Weisdorf D, Logan B, Bolaños-Meade J, Carter S, DiFronzo N, Pasquini M, Goldstein S, Ho V, Hayes-Lattin B, Wingard J, Horowitz M, Levine J; Blood and Marrow Transplant Clinical Trials Network. Etanercept, mycophenolate, denileukin or pentostatin plus corticosteroids for acute graft-versus-host disease: A randomized Phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood. 2009 Jul 16; 114(3):511-517. doi: 10.1182/blood-2009-03-212290. Epub 2009 May 14.	BMT CTN 0302 PRIMARY MANUSCRIPT	PMC2713466
10	Giralt S, Vesole DH, Somlo G, Krishnan A, Stadtmauer E, McCarthy P, Pasquini MC; Blood and Marrow Transplant Clinical Trials Network Multiple Myeloma Working Group. Re: Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: A systematic review and meta-analysis. Journal of the National Cancer Institute. 2009 Jul 1;101(13):964-967; author reply 966-967. doi: 10.1093/jnci/djp126. Epub 2009 Jun 17. [Comment on: Journal of the National Cancer Institute 101(2):100-106, 2009].	BMT CTN 0102	N/A Correspondence
2010			
11	Jacobson PA, Huang J, Wu J, Kim M, Logan B, Alousi A, Grimley M, Bolaños-Meade J, Ho V, Levine JE, Weisdorf D. Mycophenolate pharmacokinetics and association with response to acute graft-versus-host disease treatment from the Blood and Marrow Transplant Clinical Trials Network. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2010 Mar 1; 16(3):421-429. doi: 10.1016/j.bbmt.2009.11.010. Epub 2009 Nov 18.	BMT CTN 0302	PMC3104501

Number	Publication	Protocol Number	PMCID
12	Levine JE, Logan B, Wu J, Alousi AM, Ho V, Bolaños-Meade J, Weisdorf D; Blood and Marrow Transplant Clinical Trials Network. Graft-versus-host disease treatment: Predictors of survival. <i>Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation</i> . 2010 Dec 1; 16(12):1693-9. doi: 10.1016/j.bbmt.2010.05.019. Epub 2010 Jun 9.	BMT CTN 0302	PMC2955996
13	Wingard JR, Carter SL, Walsh TJ, Kurtzberg J, Small TN, Baden LR, Gersten ID, Mendizabal AM, Leather HL, Confer DL, Maziarz RT, Stadtmauer EA, Bolaños-Meade J, Brown J, DiPersio JF, Boeckh M, Marr KA; Blood and Marrow Transplant Clinical Trials Network. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. <i>Blood</i> . 2010 Dec 9; 116(24):5111-5118. doi: 10.1182/blood-2010-02-268151. Epub 2010 Sep 8.	BMT CTN 0101 PRIMARY MANUSCRIPT	PMC3012532
14	Pulsipher MA, Young NS, Tolar J, Risitano AM, Deeg HJ, Anderlini P, Calado R, Kojima S, Eapen M, Harris R, Scheinberg P, Savage S, Maciejewski JP, Tiu RV, DiFronzo N, Horowitz MM, Antin JH. Optimization of therapy for severe aplastic anemia based on clinical, biological and treatment response parameters: Conclusions of an international working group on severe aplastic anemia convened by the Blood and Marrow Transplant Clinical Trials Network, March 2010. <i>Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation</i> . 2011 Mar 1; 17(3):291-299. doi: 10.1016/j.bbmt.2010.10.028. Epub 2010 Oct 27.	BMT CTN 0301	PMC3053041
15	Tomblyn MR, Ewell M, Bredeson C, Kahl BS, Goodman SA, Horowitz MM, Vose JM, Negrin RS, Laport GG. Autologous versus reduced intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response. <i>Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation</i> . 2011 Jul 1; 17(7):1051-1057. doi: 10.1016/j.bbmt.2010.11.004. Epub 2010 Nov 10.	BMT CTN 0202 PRIMARY MANUSCRIPT	PMC3114272
16	Horwitz EM, Horowitz MM, DiFronzo NL, Kohn DB, Heslop HE; Blood and Marrow Transplant Clinical Trials Network State of the Science Cell and Gene Therapy Committee. Guidance for developing Phase II cell therapy trial proposals for consideration by the Blood and Marrow Transplant Clinical Trials Network. <i>Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation</i> . 2011 Feb 1; 17(2):192-196. doi: 10.1016/j.bbmt.2010.08.020. Epub 2010 Dec 21.	Network publication	PMC3387575

Number	Publication	Protocol Number	PMCID
2011			
17	Devine SM, Carter S, Soiffer RJ, Pasquini MC, Hari PN, Stein A, Lazarus HM, Linker C, Stadtmauer EA, Alyea EP 3rd, Keever-Taylor CA, O'Reilly RJ. Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: Results of the Blood and Marrow Transplant Clinical Trials Network protocol 0303. <i>Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation</i> . 2011 Sep 1; 17(9):1343-1351. doi: 10.1016/j.bbmt.2011.02.002. Epub 2011 Feb 12.	BMT CTN 0303 PRIMARY MANUSCRIPT	PMC3150599
18	Kohn DB, Dotti G, Brentjens R, Savoldo B, Jensen M, Cooper LJ, June C, Rosenberg S, Sadelain M, Heslop HE. CARs on track in the clinic: Workshop of the Blood and Marrow Transplant Clinical Trials Network Sub-Committee on Cell and Gene Therapy. <i>Molecular Therapy: The Journal of the American Society of Gene Therapy</i> . 2011 Mar 1; 19(3):432-438. doi: 10.1038/mt.2011.1. Epub 2011 Mar 1.	Network publication	PMC3048197
19	Brunstein CG, Fuchs EJ, Carter SL, Karanes C, Costa LJ, Wu J, Devine SM, Wingard JR, Aljithawi OS, Cutler CS, Jagasia MH, Ballen KK, Eapen M, O'Donnell PV; Blood and Marrow Transplant Clinical Trials Network. Alternative donor transplantation after reduced intensity conditioning: Results of parallel Phase 2 trials using partially HLA-mismatched related bone marrow or unrelated umbilical cord blood grafts. <i>Blood</i> . 2011 Jul 14; 118(2):282-288. doi: 10.1182/blood-2011-03-344853. Epub 2011 Apr 28.	BMT CTN 0603 / 0604 PRIMARY MANUSCRIPT	PMC3138683
20	Denzen EM, Burton Santibáñez ME, Moore H, Foley A, Gersten I, Gurgol C, Majhail NS, Spellecy R, Horowitz MM, Murphy EA. Easy-to-read informed consent forms for hematopoietic cell transplantation clinical trials. <i>Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation</i> . 2012 Feb 1; 18(2):183-189. doi: 10.1016/j.bbmt.2011.07.022. Epub 2011 Jul 30.	Network publication	PMC3242929
21	Keever-Taylor CA, Devine SM, Soiffer RJ, Mendizabal A, Carter S, Pasquini MC, Hari PN, Stein A, Lazarus HM, Linker C, Goldstein SC, Stadtmauer EA, O'Reilly RJ. Characteristics of CliniMACS® System CD34-enriched T cell-depleted grafts in a multicenter trial for acute myeloid leukemia- Blood and Marrow Transplant Clinical Trials Network (BMT CTN) protocol 0303. <i>Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation</i> . 2012 May 1; 18(5):690-697. doi: 10.1016/j.bbmt.2011.08.017. Epub 2011 Aug 26.	BMT CTN 0303	PMC3762249

Number	Publication	Protocol Number	PMCID
22	Krishnan A, Pasquini MC, Logan B, Stadtmauer EA, Vesole DH, Alyea E 3rd, Antin JH, Comenzo R, Goodman S, Hari P, Laport G, Qazilbash MH, Rowley S, Sahebi F, Somlo G, Vogl DT, Weisdorf D, Ewell M, Wu J, Geller NL, Horowitz MM, Giralt S, Maloney DG; Blood and Marrow Transplant Clinical Trials Network. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): A Phase 3 biological assignment trial. Lancet Oncology. 2011 Dec 1; 12(13):1195-1203. doi: 10.1016/S1470-2045(11)70243-1. Epub 2011 Sep 29.	BMT CTN 0102 PRIMARY MANUSCRIPT	PMC3611089
2012			
23	Kamani NR, Walters MC, Carter S, Aquino V, Brochstein JA, Chaudhury S, Eapen M, Freed BM, Grimley M, Levine JE, Logan B, Moore T, Panepinto J, Parikh S, Pulsipher MA, Sande J, Schultz KR, Spellman S, Shenoy S. Unrelated donor cord blood transplantation for children with severe sickle cell disease: Results of one cohort from the Phase II study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2012 Aug 1; 18(8):1265-1272. doi: 10.1016/j.bbmt.2012.01.019. Epub 2012 Feb 16.	BMT CTN 0601	PMC3618440
24	Levine J, Logan BR, Wu J, Alousi AM, Bolaños-Meade J, Ferrara JLM, Ho VT, Weisdorf DJ, Paczesny S. Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: A Blood and Marrow Transplant Clinical Trials Network study. Blood. 2012 Apr 19; 119(16):3854-3860. doi: 10.1182/blood-2012-01-403063. Epub 2012 Mar 1.	BMT CTN 0302	PMC3335389
25	Tolar J, Deeg HJ, Arai S, Horwitz M, Antin JH, McCarty J, Adams R, Ewell M, Leifer E, Gersten I, Carter S, Horowitz MM, Nakamura R, Pulsipher MA, DiFronzo NL, Confer DL, Eapen M, Anderlini P. Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: Early results of a cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levels. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2012 July 1; 18(7):1007-1011. doi: 10.1016/j.bbmt.2012.04.014. Epub 2012 Apr 27.	BMT CTN 0301	PMC3677744

Number	Publication	Protocol Number	PMCID
26	McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, Van Besien K, Gentile T, Isola L, Maziarz RT, Gabriel DA, Bashey A, Landau H, Martin T, Qazilbash MH, Levitan D, McClune B, Schlossman R, Hars V, Postiglione J, Jiang C, Bennett E, Barry S, Bressler L, Kelly M, Sexton M, Rosenbaum C, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Anderson KC, Linker C. Lenalidomide after stem-cell transplantation for multiple myeloma. <i>New England Journal of Medicine</i> . 2012 May 10; 366(19):1770-1781. doi: 10.1056/NEJMoa1114083.	BMT CTN 0704 / CALGB 100104 / ECOG 100104 PRIMARY MANUSCRIPT	PMC3744390
27	Pasquini MC, Devine S, Mendizabal A, Baden LR, Wingard JR, Lazarus HM, Appelbaum FR, Keever-Taylor CA, Horowitz MM, Carter S, O'Reilly RJ, Soiffer RJ. Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transplantation. <i>Journal of Clinical Oncology</i> . 2012 Sep 10; 30(26):3194-3201. doi: 10.1200/JCO.2012.41.7071. Epub 2012 Aug 6.	BMT CTN 0303	PMC3434978
28	Logan BR, Zhang MJ. The use of group sequential designs with common competing risks tests. <i>Statistics in Medicine</i> . 2013 Mar 15; 32(6):899-913. doi: 10.1002/sim.5597. Epub 2012 Sep 4.	Network publication	PMC3574186
29	Foley B, Cooley S, Verneris MR, Curtsinger J, Luo X, Waller EK, Anasetti C, Weisdorf D, Miller JS. Human cytomegalovirus (CMV)-induced memory-like NKG2C(+) NK cells are transplantable and expand in vivo in response to recipient CMV antigen. <i>Journal of Immunology</i> . 2012 Nov 15; 189(10):5082-5088. doi: 10.4049/jimmunol.1201964. Epub 2012 Oct 17.	BMT CTN 0201	PMC3490031
30	Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR, Cutler CS, Westervelt P, Woolfrey A, Couban S, Ehninger G, Johnston L, Maziarz RT, Pulsipher MA, Porter DL, Mineishi S, McCarty JM, Khan SP, Anderlini P, Bensinger WI, Leitman SF, Rowley SD, Bredeson C, Carter SL, Horowitz MM, Confer DL; Blood and Marrow Transplant Clinical Trials Network. Peripheral-blood stem cells versus bone marrow from unrelated donors. <i>New England Journal of Medicine</i> . 2012 Oct 18; 367(16):1487-1496. doi: 10.1056/NEJMoa1203517.	BMT CTN 0201 PRIMARY MANUSCRIPT	PMC3816375
31	Bolaños-Meade J, Wu J, Logan BR, Levine JE, Ho VT, Alousi AM, Weisdorf DJ, Luznik L; Blood and Marrow Transplant Clinical Trials Network. Lymphocyte phenotype during therapy for acute graft-versus-host disease: A brief report from BMT-CTN 0302. <i>Biology of Blood and Marrow Transplantation</i> . 2013 Mar 1; 19(3):481-485. doi: 10.1016/j.bbmt.2012.12.003. Epub 2012 Dec 12	BMT CTN 0302	PMC3653300

Number	Publication	Protocol Number	PMCID
2013			
32	Vose JM, Carter S, Burns LJ, Ayala E, Press O, Moskowitz CH, Stadtmauer EA, Mineishi S, Ambinder RF, Fenske TS, Horowitz MM, Fisher RI, Tomblyn M. Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with Iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: Results from the BMT CTN 0401 trial. <i>Journal of Clinical Oncology</i> . 2013 May 1; 31(13):1662-1668. doi: 10.1200/JCO.2012.45.9453. Epub 2013 Mar 11.	BMT CTN 0401 PRIMARY MANUSCRIPT	PMC3635682
33	Giralt S, McCarthy PL, Anderson KC, Carter SL, Richardson PG, Rajkumar SV, Laport GG, Stadtmauer EA, Pasquini MC, Horowitz MM. Anatomy of a successful practice-changing study: A Blood and Marrow Transplant Clinical Trials Network-National Cancer Institute Cooperative Group collaboration. <i>Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation</i> . 2013 Jun 1; 19(6):858-859. doi: 10.1016/j.bbmt.2013.03.015. Epub 2013 Mar 29.	BMT CTN 0704 / CALGB 100104 / ECOG 100104	N/A
34	Mauskopf J, Chirila C, Graham J, Gersten ID, Leather H, Maziarz RT, Baden LR, Bolaños-Meade J, Brown JM, Walsh TJ, Horowitz MH, Kurtzberg J, Marr KA, Wingard JR. Comparative cost-effectiveness analysis of voriconazole and fluconazole for prevention of invasive fungal infection in patients receiving allogeneic hematopoietic cell transplants. <i>American Journal of Health-System Pharmacy</i> . 2013 Sep 1; 70(17):1518-1527. doi: 10.2146/ajhp120599.	BMT CTN 0101	PMC4019750
35	Switzer GE, Bruce JG, Harrington D, Haagenson M, Drexler R, Foley A, Confer D, Bishop M, Anderlini P, Rowley S, Leitman SF, Anasetti C, Wingard JR. Health-related quality of life of bone marrow versus peripheral blood stem cell donors: A prespecified subgroup analysis from a Phase III RCT-BMT CTN protocol 0201. <i>Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation</i> . 2014 Jan 1; 20(1):118-127. doi: 10.1016/j.bbmt.2013.10.024. Epub 2013 Nov 1.	BMT CTN 0201	PMC3978600
36	Ferrara J. Blood and Marrow Transplant Clinical Trials Network: Progress since the State of the Science Symposium 2007. <i>Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation</i> . 2014 Feb 1; 20(2):149-153. doi: 10.1016/j.bbmt.2013.11.006. Epub 2013 Nov 12.	Network publication	PMC24239651
2014			

Number	Publication	Protocol Number	PMCID
37	Atallah E, Bylow K, Troy J, Saber W. Treatment of older patients with high-risk myelodysplastic syndromes (MDS): The emerging role of allogeneic hematopoietic stem cell transplantation (Allo HSCT). Current Hematologic Malignancy Reports. 2014 Mar 1; 9(1):57-65. doi: 10.1007/s11899-013-0195-9. Epub 2014 Jan 8.	BMT CTN 1102	PMC4031643
38	Roth JA, Bensink ME, O'Donnell PV, Fuchs EJ, Eapen M, Ramsey SD. Design of a cost-effectiveness analysis alongside a randomized trial of transplantation using umbilical cord blood versus HLA-haploidentical related bone marrow in advanced hematologic cancer. Journal of Comparative Effectiveness Research. 2014 Mar 1; 3(2):135-144. doi: 10.2217/cer.13.95.	BMT CTN 1101	PMC4036637
39	Yanik GA, Horowitz MM, Weisdorf DJ, Logan BR, Ho VT, Soiffer RJ, Carter SL, Wu J, Wingard JR, DiFronzo NL, Ferrara JL, Giralt S, Madtes DK, Drexler R, White ES, Cooke KR. Randomized, double-blind, placebo-controlled trial of soluble tumor necrosis factor receptor: Enbrel (etanercept) for the treatment of idiopathic pneumonia syndrome after allogeneic stem cell transplantation: Blood and Marrow Transplant Clinical Trials Network protocol. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2014 Jun 1; 20(6):858-864. doi: 10.1016/j.bbmt.2014.02.026. Epub 2014 Mar 7..	BMT CTN 0403 PRIMARY MANUSCRIPT	PMC4128626
40	Eapen M, O'Donnell P, Brunstein CG, Wu J, Barowski K, Mendizabal A, Fuchs EJ. Mismatched related and unrelated donors for allogeneic hematopoietic cell transplantation for adults with hematologic malignancies. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2014 Oct 1; 20(10):1485-1492. doi: 10.1016/j.bbmt.2014.05.015. Epub 2014 May 23.	BMT CTN 0603 / 0604 and 1101	PMC4163123
41	Jacobsen PB, Le-Rademacher J, Jim H, Syrjala K, Wingard JR, Logan B, Wu J, Majhail NS, Wood W, Rizzo JD, Geller NL, Kitko C, Faber E, Abidi MH, Slater S, Horowitz MM, Lee SJ. Exercise and stress management training prior to hematopoietic cell transplantation: Blood and Marrow Transplant Clinical Trial Network (BMT CTN) 0902. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2014 Oct 1; 20(10):1530-1536. doi: 10.1016/j.bbmt.2014.05.027. Epub 2014 Jun 6.	BMT CTN 0902 PRIMARY MANUSCRIPT	PMC4163109

Number	Publication	Protocol Number	PMCID
42	Saber W, Le-Rademacher J, Sekeres M, Logan B, Lewis M, Mendizabal A, Leifer E, Appelbaum F, Horowitz M, Nakamura R, Cutler C. Multicenter biologic assignment trial comparing reduced-intensity allogeneic hematopoietic cell transplant to hypomethylating therapy or best supportive care in patients aged 50 to 75 with intermediate-2 and high-risk myelodysplastic syndrome: Blood and Marrow Transplant Clinical Trials Network #1102 study rationale, design, and methods. <i>Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation</i> . 2014 Oct 1; 20(10):1566-1572. doi: 10.1016/j.bbmt.2014.06.010. Epub 2014 Jun 24.	BMT CTN 1102	PMC4169902
43	Waller EK, Logan BR, Harris WA, Devine SM, Porter DL, Mineishi M, McCarty JM, Gonzalez CE, Spitzer TR, Krijanovski OI, Linenberger ML, Woolfrey A, Howard A, Wu J, Confer DL, Anasetti A. Improved survival after transplantation of more donor plasmacytoid dendritic or naïve T cells from unrelated-donor marrow grafts: Results from BMT CTN 0201. <i>Journal of Clinical Oncology</i> . 2014 Aug 1; 32(22):2365-2372. doi: 10.1200/JCO.2013.54.4577. Epub 2014 Jun 30.	BMT CTN 0201	PMC4180368
44	Cutler C, Logan B, Nakamura R, Johnston L, Choi S, Porter D, Hogan WJ, Pasquini M, MacMillan ML, Hsu JW, Waller EK, Grupp S, McCarthy P, Wu J, Hu ZH, Carter SL, Horowitz MM, Antin JH. Tacrolimus / sirolimus vs tacrolimus / methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. <i>Blood</i> . 2014 Aug 21; 124(8):1372-1377. doi: 10.1182/blood-2014-04-567164. Epub 2014 Jun 30.	BMT CTN 0402 PRIMARY MANUSCRIPT	PMC4141519
45	Bolaños-Meade J, Logan BR, Alousi AM, Antin JH, Barowski K, Carter SL, Goldstein SC, Hexner EO, Horowitz MM, Lee SJ, Levine JE, MacMillan ML, Martin PJ, Mendizabal AM, Nakamura R, Pasquini MC, Weisdorf DJ, Westervelt P, Ho VT. Phase 3 clinical trial of steroids / mycophenolate mofetil vs steroids / placebo as therapy for acute GVHD: BMT CTN 0802. <i>Blood</i> . 2014 Nov 20; 124(22):3221-3227; quiz 3335. doi: 10.1182/blood-2014-06-577023. Epub 2014 Aug 28.	BMT CTN 0802 PRIMARY MANUSCRIPT	PMC4239331
46	Howard A, Fernandez-Vina MA, Appelbaum FR, Confer DL, Devine SM, Horowitz MM, Mendizabal A, Laport GG, Pasquini MC, Spellman SR. Recommendations for donor human leukocyte antigen assessment and matching for allogeneic stem cell transplantation: Consensus opinion of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). <i>Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation</i> . 2015 Jan 1; 21(1):4-7. doi: 10.1016/j.bbmt.2014.09.017. Epub 2014 Sep 30.	Network publication	PMC4272893

Number	Publication	Protocol Number	PMCID
47	Appelbaum F, Anasetti C, Antin J, Atkins H, Davies S, Devine S, Giralt S, Heslop H, Laport G, Lee S, Logan B, Pasquini M, Pulsipher M, Stadtmauer E, Wingard J, Horowitz M. Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2014. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2015 Feb 1; 21(2):202-224. doi: 10.1016/j.bbmt.2014.10.003. Epub 2014 Oct 15.	Network publication	PMC4426907
48	Wagner JE Jr, Eapen M, Carter S, Wang Y, Schultz KR, Wall DA, Bunin N, Delaney C, Haut P, Margolis D, Peres E, Verneris MR, Walters M, Horowitz MM, Kurtzberg J; for the Blood and Marrow Transplant Clinical Trials Network. One-unit versus two-unit cord-blood transplantation for hematologic cancers. New England Journal of Medicine. 2014 Oct 30; 371(18):1685-1694. doi: 10.1056/NEJMoa1405584.	BMT CTN 0501 PRIMARY MANUSCRIPT	PMC4257059
49	Levine JE, Braun TM, Harris AC, Holler E, Taylor A, Miller H, Magenau J, Weisdorf DJ, Ho VT, Bolaños-Meade J, Alousi AM, Ferrara JL; Blood and Marrow Transplant Clinical Trials Network. A prognostic score for acute graft-versus-host disease based on biomarkers: A multicentre study. The Lancet Haematology. 2015 Jan 1; 2(1):e21-29. doi: 10.1016/S2352-3026(14)00035-0. Epub 2014 Dec 23.	BMT CTN 0302	PMC4340092
2015			
50	MacMillan ML, Robin M, Harris AC, DeFor TE, Martin PJ, Alousi A, Ho VT, Bolaños-Meade J, Ferrara JLM, Jones R, Arora M, Blazar BR, Holtan SG, Jacobsohn D, Pasquini M, Socie G, Antin JH, Levine JE, Weisdorf DJ. A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2015 Apr 1; 21(4):761-767. doi: 10.1016/j.bbmt.2015.01.001. Epub 2015 Jan 10.	BMT CTN 0302 and 0802	PMC4359643
51	Holtan SG, Verneris MR, Schultz KR, Newell LF, Meyers G, He F, DeFor TE, Vercellotti GM, Slungaard A, MacMillan ML, Cooley SA, Blazar BR, Panoskaltsis-Mortari A, Weisdorf DJ. Circulating angiogenic factors associated with response and survival in patients with acute graft-versus-host disease: Results from Blood and Marrow Transplant Clinical Trials Network 0302 and 0802. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2015 Jun 1; 21(6):1029-1036. doi: 10.1016/j.bbmt.2015.02.018. Epub 2015 Mar 7.	BMT CTN 0302 and 0802	PMC4426052

Number	Publication	Protocol Number	PMCID
52	Khera N, Majhail NS, Brazauskas R, Wang Z, He N, Aljurf MD, Akpek G, Atsuta Y, Beattie S, Bredeson CN, Burns LJ, Dalal JD, Freytes CO, Gupta V, Inamoto Y, Lazarus HM, LeMaistre CF, Steinberg A, Szwajcer D, Wingard JR, Wirk B, Wood WA, Joffe S, Hahn TE, Loberiza FR, Anasetti C, Horowitz MM, Lee SJ. Comparison of characteristics and outcomes of trial participants and nonparticipants: Example of Blood and Marrow Transplant Clinical Trials Network 0201 trial. <i>Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation</i> . 2015 Oct 1; 21(10):1815-1822. doi: 10.1016/j.bbmt.2015.06.004. Epub 2015 Jun 11.	BMT CTN 0201	PMC4568172
53	Anderlini P, Wu J, Gersten I, Ewell M, Tolar J, Antin JH, Adams R, Arai S, Eames G, Horwitz ME, McCarty J, Nakamura R, Pulsipher MA, Rowley S, Leifer E, Carter SL, DiFronzo NL, Horowitz MM, Confer D, Deeg HJ, Eapen M. Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: A Phase 1-2 dose de-escalation study. <i>The Lancet Haematology</i> . 2015 Sep 1; 2(9):e367-375. doi: 10.1016/S2352-3026(15)00147-7. Epub 2015 Sep 2.	BMT CTN 0301 PRIMARY MANUSCRIPT	PMC4861234
54	Young JH, Logan BR, Wu J, Wingard JR, Weisdorf DJ, Mudrick C, Knust K, Horowitz MM, Confer DL, Dubberke ER, Pergam SA, Marty FM, Strasfeld LM, Brown JWM, Langston AA, Schuster MG, Kaul DR, Martin SI, Anasetti C; Blood and Marrow Transplant Clinical Trials Network Trial 0201. Infections after transplantation of bone marrow or peripheral blood stem cells from unrelated donors. <i>Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation</i> . 2016 Feb 1; 22(2):359-370. doi: 10.1016/j.bbmt.2015.09.013. Epub 2015 Sep 25.	BMT CTN 0201	PMC4716871

Number	Publication	Protocol Number	PMCID
55	Giralt S, Garderet L, Durie B, Cook G, Gahrton G, Bruno B, Hari P, Lokhorst H, McCarthy P, Krishnan A, Sonneveld P, Goldschmidt H, Jagannath S, Barlogie B, Mateos M, Gimsing P, Sezer O, Mikhael J, Lu J, Dimopoulos M, Mazumder A, Palumbo A, Abonour R, Anderson K, Attal M, Blade J, Bird J, Cavo M, Comenzo R, de la Rubia J, Einsele H, Garcia-Sanz R, Hillengass J, Holstein S, Johnsen HE, Joshua D, Koehne G, Kumar S, Kyle R, Leleu X, Lonial S, Ludwig H, Nahi H, Nooka A, Orlowski R, Rajkumar V, Reiman A, Richardson P, Riva E, San Miguel J, Tureson I, Usmani S, Vesole D, Bensinger W, Qazilbash M, Efebera Y, Mohty M, Gasparreto C, Gajewski J, LeMaistre CF, Bredeson C, Moreau P, Pasquini M, Kroeger N, Stadtmauer E. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group consensus conference on salvage hematopoietic cell transplantation in patients with relapsed multiple myeloma. <i>Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation</i> . 2015 Dec 1; 21(12):2039-2051. doi: 10.1016/j.bbmt.2015.09.016. Epub 2015 Sep 30.	Network publication	PMC4757494
56	Wood WA, Le-Rademacher J, Syrjala KL, Jim H, Jacobsen PB, Knight JM, Abidi MH, Wingard JR, Majhail NS, Geller NL, Rizzo JD, Fei M, Wu J, Horowitz MM, Lee SJ. Patient-reported physical functioning predicts the success of hematopoietic cell transplantation (BMT CTN 0902). <i>Cancer</i> . 2016 Jan 1; 122(1):91-98. doi: 10.1002/cncr.29717. Epub 2015 Oct 6.	BMT CTN 0902	PMC4707096
57	Devine SM, Owzar K, Blum W, Mulkey F, Stone RM, Hsu JW, Champlin RE, Chen YB, Vij R, Slack J, Soiffer RJ, Larson RA, Shea TC, Hars V, Sibley AB, Giralt S, Carter S, Horowitz MM, Linker C, Alyea EP. Phase II study of allogeneic transplantation for older patients with acute myeloid leukemia in first complete remission using a reduced-intensity conditioning regimen: Results from Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology) / Blood and Marrow Transplant Clinical Trial Network 0502. <i>Journal of Clinical Oncology</i> . 2015 Dec 10; 33(35):4167-4175. doi: 10.1200/JCO.2015.62.7273. Epub 2015 Nov 2.	BMT CTN 0502 / CALGB 100103 PRIMARY MANUSCRIPT	PMC4658453
2016			

Number	Publication	Protocol Number	PMCID
58	Rashidi A, DiPersio JF, Sandmaier BM, Colditz GA, Weisdorf DJ. Steroids versus steroids plus additional agent in frontline treatment of acute graft-versus-host disease: A systematic review and meta-analysis of randomized trials. <i>Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation</i> . 2016 Jun 1; 22(6):1133-1137. doi: 10.1016/j.bbmt.2016.02.021. Epub 2016 Mar 10.	BMT CTN 0802	PMC5045896
59	Burns LJ, Logan BR, Chitphakdithai P, Miller JP, Drexler R, Spellman S, Switzer GE, Wingard JR, Anasetti C, Confer DL; Blood and Marrow Transplant Clinical Trials Network. Recovery of unrelated donors of peripheral blood stem cells versus recovery of unrelated donors of bone marrow: A prespecified analysis from the Phase III Blood and Marrow Transplant Clinical Trials Network protocol 0201. <i>Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation</i> . 2016 Jun 1; 22(6):1108-1116. doi: 10.1016/j.bbmt.2016.02.018. Epub 2016 Mar 21.	BMT CTN 0201	PMC4867293
60	Laport GG, Wu J, Logan B, Bachanova V, Hosing C, Fenske T, Longo W, Devine SM, Nademanee A, Gersten I, Horowitz M, Lazarus HM, Riches ML; Blood and Marrow Transplant Clinical Trials Network. Reduced-intensity conditioning with fludarabine, cyclophosphamide, and high-dose rituximab for allogeneic hematopoietic cell transplantation for follicular lymphoma: A Phase two multicenter trial from the Blood and Marrow Transplant Clinical Trials Network. <i>Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation</i> . 2016 Aug 1; 22(8):1440-1448. doi: 10.1016/j.bbmt.2016.04.014. Epub 2016 Apr 23.	BMT CTN 0701 PRIMARY MANUSCRIPT	PMC4949103
61	Hope WW, Walsh TJ, Goodwin J, Peloquin CA, Howard A, Kurtzberg J, Mendizabal A, Confer DL, Bulitta J, Baden LR, Neely MN, Wingard JR; Blood and Marrow Transplant Clinical Trials Network. Voriconazole pharmacokinetics following HSCT: Results from the BMT CTN 0101 trial. <i>The Journal of Antimicrobial Chemotherapy</i> . 2016 Aug 1; 71(8):2234-2240. doi: 10.1093/jac/dkw127. Epub 2016 Apr 27.	BMT CTN 0101	PMC4954923
62	Shaw BE, Lee SJ, Horowitz MM, Wood WA, Rizzo, JD, Flynn KE. Can we agree on patient-reported outcome measures for assessing hematopoietic cell transplantation patients? A study from the CIBMTR and BMT CTN. <i>Bone Marrow Transplantation</i> . 2016 Sep 1; 51(9):1173-1179. doi: 10.1038/bmt.2016.113. Epub 2016 May 9.	Network publication	PMID 27159181

Number	Publication	Protocol Number	PMCID
63	Alvarnas JC, Le-Rademacher J, Wang Y, Little RF, Akpek G, Ayala E, Devine S, Baiocchi R, Lozanski G, Kaplan L, Noy A, Popat U, Hsu J, Morris LE Jr, Thompson J, Horowitz MM, Mendizabal A, Levine A, Krishnan A, Forman SJ, Navarro WH, Ambinder R. Autologous hematopoietic cell transplantation for HIV-related lymphoma: Results of the BMT CTN 0803 / AMC 071 trial. Blood. 2016 Aug 25; 128(8):1050-1058. doi: 10.1182/blood-2015-08-664706. Epub 2016 Jun 13.	BMT CTN 0803 PRIMARY MANUSCRIPT	PMC5000843
64	D'Souza A, Pasquini M, Logan B, Giralto S, Krishnan A, Antin J, Howard A, Goodman S, Qazilbash M, Knust K, Sahebi F, Weisdorf D, Vesole D, Stadtmauer E, Maloney D, Hari P. Heavy / light chain ratio normalization prior to transplant is of independent prognostic significance in multiple myeloma: A BMT CTN 0102 correlative study. British Journal of Haematology. 2017 Sep 1; 178(5):816-819. doi: 10.1111/bjh.14170. Epub 2016 Jun 13.	BMT CTN 0102	PMC5154782
65	Steering Committee of the Blood and Marrow Transplant Clinical Trials Network. The Blood and Marrow Transplant Clinical Trials Network: An effective infrastructure for addressing important issues in hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2016 Oct 1;22(10):1747-1757. doi: 10.1016/j.bbmt.2016.07.003. Epub 2016 Jul 11.	Network 10 Year Publication	PMC5027144
66	Lee SJ, Logan B, Westervelt P, Cutler C, Woolfrey A, Khan SP, Waller EK, Maziarz RT, Wu J, Shaw B, Confer D, Horowitz MM, Anasetti C. Comparison of patient-reported outcomes in 5-year survivors who received bone marrow vs peripheral blood unrelated donor transplantation: Long-term follow-up of a randomized clinical trial. JAMA Oncology. 2016 Dec 1; 2(12):1583-1589. doi: 10.1001/jamaoncol.2016.2520. Epub 2016 Aug 11.	BMT CTN 0201	PMC5145732
67	Jim HSL, Sutton SK, Small BJ, Jacobsen PB, Wood WA, Knight JM, Majhail NS, Syrjala KL, Lee SJ. Trajectories of quality of life after hematopoietic cell transplantation: Secondary analysis of Blood and Marrow Transplant Clinical Trials Network 0902 data. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2016 Nov 1; 22(11):2077-2083. doi: 10.1016/j.bbmt.2016.08.012. Epub 2016 Aug 15.	BMT CTN 0902	PMC5068568

Number	Publication	Protocol Number	PMCID
68	O'Donnell PV, Eapen M, Horowitz MM, Logan BR, DiGilio A, Brunstein C, Fuchs E, Flowers ME, Salit R, Raj K, Pagliuca A, Bradstock K, Granata A, Castagna L, Fürst S, Blaise D. Comparable outcomes with marrow or peripheral blood as stem cell sources for hematopoietic cell transplantation from haploidentical donors after non-ablative conditioning: A matched-pair analysis. Bone Marrow Transplantation. 2016 Dec 1; 51(12):1599-1601. doi: 10.1038/bmt.2016.215. Epub 2016 Aug 15.	BMT CTN 0603	PMC5143194
69	Knight JM, Syrjala KL, Majhail NS, Martens M, Le-Rademacher J, Logan BR, Lee SJ, Jacobsen PB, Wood WA, Jim HS, Wingard JR, Horowitz MM, Abidi MH, Fei M, Rawls L, Rizzo JD. Patient-reported outcomes and socioeconomic status as predictors of clinical outcomes after hematopoietic stem cell transplantation: A study from the Blood and Marrow Transplant Clinical Trials Network 0902 trial. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2016 Dec 1; 22(12):2256-2263. doi: 10.1016/j.bbmt.2016.08.016. Epub 2016 Aug 23.	BMT CTN 0902	PMC5116244
70	Shenoy S, Eapen M, Panepinto JA, Logan BR, Wu J, Abraham A, Brochstein J, Chaudhury S, Godder K, Haight AE, Kasow KA, Leung K, Andreansky M, Bhatia M, Dalal J, Haines H, Jaroscak J, Lazarus H, Levine JE, Krishnamurti L, Margolis D, Megason GC, Yu LC, Pulsipher MA, Gersten I, DiFronzo N, Horowitz M, Walters MC, Kamani N. A trial of unrelated donor marrow transplantation for children with severe sickle cell disease. Blood. 2016 Nov 24; 128(21):2561-2567. doi: 10.1182/blood-2016-05-715870. Epub 2016 Sep 13.	BMT CTN 0601 PRIMARY MANUSCRIPT	PMC5123194
71	Wingard J, Wood WA, Martens M, Le-Rademacher J, Logan B, Knight J, Jacobsen PB, Jim H, Majhail NS, Syrjala K, Rizzo JD, Lee SJ. Pretransplantation exercise and hematopoietic cell transplantation survival: A secondary analysis of Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0902). Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2017 Jan 1; 23(1):161-164. doi: 10.1016/j.bbmt.2016.10.007. Epub 2016 Oct 11.	BMT CTN 0902	PMC5182134
72	Abu Zaid M, Wu J, Wu C, Logan BR, Yu J, Cutler C, Antin JH, Paczesny S, Choi SW. Plasma biomarkers of risk for death in a multicenter Phase 3 trial with uniform transplant characteristics post-allogeneic HCT. Blood. 2017 Jan 12; 129(2):162-170. doi: 10.1182/blood-2016-08-735324. Epub 2016 Nov 8.	BMT CTN 0402	PMC5234220

Number	Publication	Protocol Number	PMCID
73	Syrjala KL, Sutton SK, Jim HSL, Knight JM, Wood WA, Lee SJ, Jacobsen PB, Abidi MH, Yi JC. Cancer and treatment distress psychometric evaluation over time: A BMT CTN 0902 secondary analysis. <i>Cancer</i> . 2017 Apr 15; 123(8):1416-1423. doi: 10.1002/cncr.30454. Epub 2016 Nov 28.	BMT CTN 0902	PMC5384862
74	Ravandi F, Othus M, O'Brien S, Forman SJ, Ha CS, Wong JYC, Tallman MS, Paietta E, Racevskis J, Uy GL, Horowitz M, Takebe N, Little R, Borate U, Kebriaei P, Kingsbury L, Kantarjian H, Radich JP, Erba HP, Appelbaum FR. US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL. <i>Blood Advances</i> . 2016 Dec 27;1(3):250-259. doi: 10.1182/bloodadvances.2016001495. Epub 2016 Dec 19.	BMT CTN 0805 / SWOG S0805 PRIMARY MANUSCRIPT	PMC5642915
2017			
75	Scott BL, Pasquini MC, Logan BR, Wu J, Devine SM, Porter DL, Maziarz RT, Warlick E, Fernandez HF, Alyea E, Hamadani M, Bashey A, Giralt S, Geller NL, Leifer E, Le-Rademacher J, Mendizabal A, Horowitz MM, Deeg HJ, Horwitz ME. Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes. <i>Journal of Clinical Oncology</i> . 2017 Apr 10; 35(11):1154-1161. doi: 10.1200/JCO.2016.70.7091. Epub 2017 Feb 13.	BMT CTN 0901 PRIMARY MANUSCRIPT	PMC5455603
76	Arora M, Weisdorf DJ, Shanley RM, Thyagarajan B. Pharmacogenetics of steroid-responsive acute graft-versus-host disease. <i>Clinical Transplantation</i> . 2017 May 1; 31(5):10.1111/ctr.12949. doi: 10.1111/ctr.12949. Epub 2017 Apr 4.	BMT CTN 0302	PMC5413396
77	Holtan SG, Newell LF, Cutler C, Verneris MR, DeFor TE, Wu J, Howard A, MacMillan ML, Antin JH, Blazar BR, Weisdorf DJ, Panoskaltsis-Mortari A. Low EGF in myeloablative allotransplantation: Association with severe acute GvHD in BMT CTN 0402. <i>Bone Marrow Transplantation</i> . 2017 Sep 1; 52(9):1300-1303. doi: 10.1038/bmt.2017.89. Epub 2017 Jun 5.	BMT CTN 0402	PMC5699445
78	Eapen M, Kurtzberg J, Zhang M, Hattersely G, Fei M, Mendizabal A, Chan KW, De Oliveira S, Schultz KR, Wall D, Horowitz MM, Wagner JE. Umbilical cord blood transplantation in children with acute leukemia: Impact of conditioning on transplantation outcomes. <i>Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation</i> . 2017 Oct 1; 23(10):1714-1721. doi: 10.1016/j.bbmt.2017.06.023. Epub 2017 Jul 3.	BMT CTN 0501	PMC5605440

Number	Publication	Protocol Number	PMCID
79	Holstein SA, Jung SH, Richardson PG, Hofmeister CC, Hurd DD, Hassoun H, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, van Beisen K, Gentile TG, Isola L, Maziarz RT, Bashey A, Landau H, Martin T, Qazilbash MH, Rodriguez C, McClune B, Schlossman RL, Smith SE, Hars V, Owzar K, Jiang C, Boyd M, Schultz C, Wilson M, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Linker C, Anderson KC, McCarthy PL. Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: A randomised, double-blind, Phase 3 trial. The Lancet Haematology. 2017 Sep 1; 4(9):e431-e442. doi: 10.1016/S2352-3026(17)30140-0. Epub 2017 Aug 17. Erratum in: Lancet Haematology. 2018 Aug 1; 5(8):e332. Erratum in: Lancet Haematol. 2018 Dec 1; 5(12):e608.	BMT CTN 0704 / CALGB 100104 / ECOG 100104	PMC5718627
80	Turcotte LM, DeFor TE, Newell LF, Cutler CS, Verneris MR, Wu J, Howard A, MacMillan ML, Antin JH, Vercellotti GM, Slungaard A, Blazar BR, Weisdorf DJ, Panoskaltsis-Mortari A, Holtan SG. Donor and recipient plasma follistatin levels are associated with acute GvHD in Blood and Marrow Transplant Clinical Trials Network 0402. Bone Marrow Transplantation. 2018 Jan 1; 53(1):64-68. doi: 10.1038/bmt.2017.236. Epub 2017 Oct 23.	BMT CTN 0402	PMC5752567
81	Holstein SA, Avet-Loiseau H, Hahn T, Ho CM, Lohr JG, Munshi NC, Paiva B, Pasquini MC, Tarrio JD Jr, Usmani SZ, Wallace PK, Weisel K, McCarthy PL. BMT CTN myeloma intergroup workshop on minimal residual disease and immune profiling: Summary and recommendations from the organizing committee. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2018 Apr 1; 24(4):641-648. doi: 10.1016/j.bbmt.2017.12.774. Epub 2017 Dec 11.	Network publication	PMC5902638
82	Smith EP, Li H, Friedberg JW, Constine LS, Rimsza LM, Cook JR, Laport GG, Popplewell LL, Holmberg LA, Smith SM, LeBlanc M, Forman SJ, Fisher RI, Stiff PJ. Tandem autologous hematopoietic cell transplantation for patients with primary progressive or recurrent Hodgkin lymphoma: A SWOG and Blood and Marrow Transplant Clinical Trials Network Phase II trial (SWOG S0410 / BMT CTN 0703). Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2018 Apr 1; 24(4):700-707. doi: 10.1016/j.bbmt.2017.12.798. Epub 2017 Dec 28.	BMT CTN 0703 / SWOG S0410 PRIMARY MANUSCRIPT	PMC5965270
2018			

Number	Publication	Protocol Number	PMCID
83	Pasquini MC, Logan B, Jones RJ, Alousi AM, Appelbaum FR, Bolaños-Meade J, Flowers ME, Giralt S, Horowitz MM, Jacobsohn D, Koreth J, Levine JE, Luznik L, Maziarz R, Mendizabal A, Pavletic S, Perales MA, Porter D, Reshef R, Weisdorf D, Antin JH. Blood and Marrow Transplant Clinical Trials Network report on development of novel endpoints and selection of promising approaches for graft-versus-host disease prevention trials. <i>Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation</i> . 2018 Jun 1; 24(6):1274-1280. doi: 10.1016/j.bbmt.2018.01.002. Epub 2018 Jan 8.	BMT CTN 1203 and 1301	PMC5993573
84	Andermann TM, Peled JU, Ho C, Reddy P, Riches M, Storb R, Teshima T, van den Brink M, Alousi A, Balderman S, Chiusolo P, Clark WB, Holler E, Howard A, Kean LS, Koh AY, McCarthy PL, McCarty JM, Mohty M, Nakamura R, Rezvani K, Segal BH, Shaw BE, Shpall EJ, Sung AD, Weber D, Whangbo J, Wingard JR, Wood WA, Perales MA, Jenq RR, Bhatt AS; Blood and Marrow Transplant Clinical Trials Network. The microbiome and hematopoietic cell transplantation: Past, present, and future. <i>Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation</i> . 2018 Jul 1; 24(7):1322-1340. doi: 10.1016/j.bbmt.2018.02.009. Epub 2018 Feb 19.	Network Publication	PMC6045977
85	Jim HSL, Sutton S, Majhail NS, Wood WA, Jacobsen PB, Wingard JR, Wu J, Knight JM, Syrjala KL, Lee SJ. Severity, course, and predictors of sleep disruption following hematopoietic cell transplantation: A secondary data analysis from the BMT CTN 0902 trial. <i>Bone Marrow Transplantation</i> . 2018 Aug 1; 53(8):1038-1043. doi: 10.1038/s41409-018-0138-0. Epub 2018 Mar 7.	BMT CTN 0902	PMC6064383
86	Rashidi A, Shanley R, Yohe SL, Thyagarajan B, Curtsinger J, Anasetti C, Waller EK, Miller JS, Blazar BR, Weisdorf DJ. Association between recipient TNF rs361525 and acute GVHD: Results from analysis of BMT CTN-0201 samples. <i>Bone Marrow Transplantation</i> . 2018 Aug 1; 53(8):1069-1071. doi: 10.1038/s41409-018-0127-3. Epub 2018 Mar 7	BMT CTN 0201	PMC6064382
87	Martens MJ, Logan BR. A group sequential test for treatment effect based on the Fine-Gray model. <i>Biometrics</i> . 2018 Sep 1; 74(3):1006-1013. doi: 10.1111/biom.12871. Epub 2018 Mar 13.	Network Publication	PMC6146968

Number	Publication	Protocol Number	PMCID
88	Spellecy R, Tarima S, Denzen E, Moore H, Abhyankar S, Dawson P, Foley A, Gersten I, Horwitz M, Idossa L, Joffe S, Kamani N, King R, Lazaryan A, Morris L, Horowitz MM, Majhail NS. Easy-to-read informed consent form for hematopoietic cell transplantation clinical trials: Results from the Blood and Marrow Transplant Clinical Trials Network 1205 study. <i>Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation</i> . 2018 Oct 1; 24(10):2145-2151. doi: 10.1016/j.bbmt.2018.04.014. Epub 2018 Apr 18.	BMT CTN 1205 PRIMARY MANUSCRIPT	PMC6193865
89	Carpenter PA, Logan BR, Lee SJ, Weisdorf DJ, Johnston L, Costa LJ, Kitko CL, Bolaños-Meade J, Sarantopoulos S, Alousi AM, Abhyankar S, Waller EK, Mendizabal A, Zhu J, O'Brien KA, Lazaryan A, Wu J, Nemecek ER, Pavletic SZ, Cutler CS, Horowitz MM, Arora M; BMT CTN. A Phase II/III randomized, multicenter trial of prednisone/sirolimus <i>versus</i> prednisone/sirolimus/calcineurin inhibitor for the treatment of chronic graft- <i>versus</i> -host disease: BMT CTN 0801. <i>Haematologica</i> . 2018 Nov 1; 103(11):1915-1924. doi: 10.3324/haematol.2018.195123. Epub 2018 Jun 28.	BMT CTN 0801 PRIMARY MANUSCRIPT	PMC6278959
90	Khera N, Mau LW, Denzen EM, Meyer C, Houg K, Lee SJ, Horowitz MM, Burns LJ. Translation of clinical research into practice: An impact assessment of the results from the Blood and Marrow Transplant Clinical Trials Network protocol 0201 on unrelated graft source utilization. <i>Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation</i> . 2018 Nov 1; 24(11):2204-2210. doi: 10.1016/j.bbmt.2018.06.028. Epub 2018 Jun 30.	BMT CTN 0201	PMC6242749
91	Allen CE, Marsh R, Dawson P, Bollard CM, Shenoy S, Roehrs P, Hanna R, Burroughs L, Kean L, Talano JA, Schultz KR, Pai SY, Baker KS, Andolina JR, Stenger EO, Connolly J, Ramirez A, Bryant C, Eapen M, Pulsipher MA. Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies. <i>Blood</i> . 2018 Sep 27; 132(13):1438-1451. doi: 10.1182/blood-2018-01-828277. Epub 2018 Jul 11.	BMT CTN 1204 PRIMARY MANUSCRIPT	PMC6161764
92	Rashidi A, Shanley R, Yohe SL, Thyagarajan B, Curtsinger J, Anasetti C, Waller EK, Scott BL, Blazar BR, Weisdorf DJ. Recipient single nucleotide polymorphisms in paneth cell antimicrobial peptide genes and acute graft- <i>versus</i> -host disease: Analysis of BMT CTN-0201 and -0901 samples. <i>British Journal of Haematology</i> . 2018 Sep 1; 182(6):887-894. doi: 10.1111/bjh.15492. Epub 2018 Jul 13.	BMT CTN 0201 and 0901	PMC6128755

Number	Publication	Protocol Number	PMCID
93	Holtan SG, DeFor TE, Panoskaltsis-Mortari A, Khera N, Levine JE, Flowers MED, Lee SJ, Inamoto Y, Chen GL, Mayer S, Arora M, Palmer J, Cutler CS, Arai S, Lazaryan A, Newell LF, Jagasia MH, Pusic I, Wood WA, Renteria AS, Yanik G, Hogan WJ, Hexner E, Ayuk F, Holler E, Bunworasate U, Efebera YA, Ferrara JLM, Pidala J, Howard A, Wu J, Bolaños-Meade J, Ho V, Alousi A, Blazar BR, Weisdorf DJ, MacMillan ML. Amphiregulin modifies the Minnesota acute graft-versus-host disease risk score: Results from BMT CTN 0302/0802. Blood Advances. 2018 Aug 14; 2(15):1882-1888. doi: 10.1182/bloodadvances.2018017343. Epub 2018 Aug 7.	BMT CTN 0302 / 0802	PMC6093743
94	Rashidi A, Shanley R, Anasetti C, Waller EK, Scott BL, Blazar BR, Weisdorf DJ. Analysis of BMT CTN-0201 and -0901 samples did not reproduce the reported association between recipient REG3A rs7588571 and chronic GVHD. Bone Marrow Transplantation. 2019 Mar 1; 54(3):490-493. doi: 10.1038/s41409-018-0331-1. Epub 2018 Aug 31.	BMT CTN 0201 / 0901	PMC6395530
95	Rashidi A, Wangjam T, Bhatt AS, Weisdorf DJ, Holtan SG; on behalf of BMT CTN Investigators. Antibiotic practice patterns in hematopoietic cell transplantation: A survey of Blood and Marrow Transplant Clinical Trials Network centers. American Journal of Hematology. 2018 Nov 1; 93(11):E348-E350. doi: 10.1002/ajh.25236. Epub 2018 Sep 9	Network Publication	PMC6196101
96	Holstein SA, Ye JC, Howard A, Bhutani M, Gormley N, Hahn T, Hillengass J, Krishnan A, Landgren CO, Munshi NC, Oliva S, Owen RG, Pasquini MC, Puig N, Weinhold N, Weisel K, McCarthy PL. Summary of the second annual BMT CTN myeloma intergroup workshop on minimal residual disease and immune profiling. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation.. 2019 Mar 1; 25(3):e89-e97. doi: 10.1016/j.bbmt.2018.11.001. Epub 2018 Nov 5.	Network Publication	PMC6445685
2019			
97	King AA, McKinstry RC, Wu J, Eapen M, Abel R, Varughese T, Kamani N, Shenoy S. Functional and radiologic assessment of the brain after reduced-intensity unrelated donor transplantation for severe sickle cell disease: Blood and Marrow Transplant Clinical Trials Network study 0601. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2019 May 1; 25(5):e174-e178. doi: 10.1016/j.bbmt.2019.01.008. Epub 2019 Jan 11.	BMT CTN 0601	PMC6511327

Number	Publication	Protocol Number	PMCID
98	Stadtmauer EA, Pasquini MC, Blackwell B, Hari P, Bashey A, Devine S, Efebera Y, Ganguly S, Gasparetto C, Geller N, Horowitz MM, Koreth J, Knust K, Landau H, Brunstein C, McCarthy P, Nelson C, Qazilbash MH, Shah N, Vesole DH, Vij R, Vogl, DT, Giralt S, Somlo G, Krishnan A. Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: Results of the BMT CTN 0702 trial. <i>Journal of Clinical Oncology</i> . 2019 Mar 1; 37(7):589-597. doi:10.1200/JCO.18.00685. Epub 2019 Jan 17.	BMT CTN 0702 PRIMARY MANUSCRIPT	PMC6553842
99	Paul J, Nakasone H, Sahaf B, Wu F, Wang K, Ho V, Wu J, Kim H, Blazar BR, Ritz J, Howard A, Cutler C, Miklos D. A confirmation of chronic graft-versus-host disease prediction using allogeneic HY antibodies following sex-mismatched hematopoietic cell transplantation. <i>Haematologica</i> . 2019 Jul 1; 104(7):e314-e317. doi:10.3324/haematol.2018.199646. Epub 2019 Jan 17.	BMT CTN 0402 / 0201	PMC6601098
100	Bolaños-Meade J, Reshef R, Fraser R, Fei M, Abhyankar S, Al-Kadhimi Z, Alousi AM, Antin JH, Arai S, Bickett K, Chen YB, Damon LE, Efebera YA, Geller NL, Giralt SA, Hari P, Holtan SG, Horowitz MM, Jacobsohn DA, Jones RJ, Liesveld JL, Logan BR, MacMillan ML, Mielcarek M, Noel P, Pidala J, Porter DL, Pusic I, Sobecks R, Solomon SR, Weisdorf DJ, Wu J, Pasquini MC, Koreth J. Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: A randomised Phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203). <i>The Lancet Haematology</i> . 2019 Mar 1; 6(3):PE132-E142. doi:10.1016/S2352-3026(18)30221-7.	BMT CTN 1203 PRIMARY MANUSCRIPT	PMC6503965
101	Levis MJ, Chen YB, Hamadani M, Horowitz MM, Jones RJ; Blood and Marrow Transplant Clinical Trials Network. FLT3 inhibitor maintenance after allogeneic transplantation: Is a placebo-controlled, randomized trial ethical? <i>Journal of Clinical Oncology</i> . 2019 Jul 1; 37(19):1604-1607. doi:10.1200/JCO.19.00321. Epub 2019 Apr 29.	BMT CTN 1506	PMC6804888

Number	Publication	Protocol Number	PMCID
102	Gooptu M, Kim HT, Howard A, Choi SW, Soiffer RJ, Antin JH, Ritz J, Cutler CS. Effect of sirolimus on immune reconstitution following myeloablative allogeneic stem cell transplantation: An ancillary analysis of a randomized controlled trial comparing tacrolimus/sirolimus and tacrolimus/methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402). <i>Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation</i> . 2019 Nov 1; 25(11):2143-2151. doi:10.1016/j.bbmt.2019.06.029. Epub 2019 Jul 2.	BMT CTN 0402	PMC7304072
103	Ambinder RF, Wu J, Logan B, Durand CM, Shields R, Popat UR, Little RF, McMahon DK, Cyktor J, Mellors JW, Ayala E, Kaplan LD, Noy A, Jones RJ, Howard A, Forman SJ, Porter D, Arce-Lara C, Shaughnessy P, Sproat L, Hashmi SK, Mendizabal AM, Horowitz MM, Navarro WH, Alvarnas JC. Allogeneic hematopoietic cell transplant for HIV patients with hematologic malignancies: The BMT CTN-0903/AMC-080 trial. <i>Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation</i> . 2019 Nov 1; 25(11):2160-2166. doi:10.1016/j.bbmt.2019.06.033. Epub 2019 Jul 4.	BMT CTN 0903 / AMC-080 PRIMARY MANUSCRIPT	PMC6907401
104	Waller EK, Logan BR, Fei M, Lee SJ, Confer D, Howard A, Chandrakasan S, Anasetti C, Fernando SM, Giver CR. Kinetics of immune cell reconstitution predict survival in allogeneic bone marrow and G-CSF-mobilized stem cell transplantation. <i>Blood Advances</i> . 2019 Aug 13; 3(15):2250-2263. doi:10.1182/bloodadvances.2018029892. Epub 2019 Jul 25.	BMT CTN 0201	PMC6693008
105	Efebera Y, Ruppert A, Ngankeu A, Garman S, Kumchala P, Howard A, Devine S, Ranganathan P, Garzon R. Serum microRNA-155 in acute graft-versus-host-disease (aGVHD). <i>International Journal of Bone Marrow Research</i> . 2019; 2:079-82. doi: 10.29328/journal.ijbmr.1001007. Epub 2019 Aug 16.	BMTCTN 0101	PMC8168723
106	Rashidi A, Luo X, Cooley S, Anasetti C, Waller EK, Brunstein CG, Cichocki F, Weisdorf DJ, Miller JS. The association of CMV with NK-cell reconstitution depends on graft source: Results from BMT CTN-0201 samples. <i>Blood Advances</i> . 2019 Aug 27; 3(16):2465-2469. doi:10.1182/bloodadvances.2019000298. Epub 2019 Aug 19.	BMT CTN 0201	PMC6712525

Number	Publication	Protocol Number	PMCID
107	Holstein SA, Al-Kadhimi Z, Costa LJ, Hahn T, Hari P, Hillengass J, Jacob A, Munshi NC, Oliva S, Pasquini MC, Shi Q, Stadtmauer EA, Waldvogel SL, McCarthy PL. Summary of the third annual Blood and Marrow Transplant Clinical Trials Network myeloma intergroup workshop on minimal residual disease and immune profiling. <i>Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation</i> . 2020 Jan 1; 26(1):e7-e15. doi:10.1016/j.bbmt.2019.09.015. Epub 2019 Sep 14.	Network Publication	PMC6942175
108	Newell LF, DeFor TE, Cutler C, Verneris MR, Blazar BR, Miller JS, Antin JH, Howard A, Wu J, MacMillan ML, Panoskaltsis-Mortari A, Weisdorf DJ, Holtan SG. Follistatin and soluble endoglin predict 1-year nonrelapse mortality after allogeneic hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation</i> . 2020 Mar 1; 26(3):606-611. doi:10.1016/j.bbmt.2019.11.006. Epub 2019 Nov 10.	BMT CTN 0402	PMC7219549
109	Martens MJ, Logan BR. Group sequential tests for treatment effect on survival and cumulative incidence at a fixed time point. <i>Lifetime Data Analysis</i> . 2020 Jul 1; 26(3):603-623. doi:10.1007/s10985-019-09491-z. Epub 2019 Nov 15.	BMT CTN 0402	PMC7365590
110	Pidala J, Hamadani M, Dawson P, Martens M, Alousi AM, Jagasia M, Efebera YA, Chhabra S, Pusic I, Holtan SG, Ferrara JL, Levine JE, Mielcarek M, Anasetti C, Antin JH, Bolanos-Meade J, Howard A, Logan BR, Leifer E, Pritchard TS, Horowitz MM, MacMillan ML. Randomized multicenter trial of sirolimus vs. prednisone as initial therapy for standard risk acute GVHD: The BMT CTN 1501 trial. <i>Blood</i> . 2020 Jan 9; 135(2):97-107. doi: 10.1182/blood.2019003125. Epub 2019 Nov 18.	BMT CTN 1501 PRIMARY MANUSCRIPT	PMC6952830
111	Giralt S, Costa LJ, Maloney D, Krishnan A, Fei M, Antin JH, Brunstein C, Geller N, Goodman S, Hari P, Logan B, Lowsky R, Qazilbash MH, Sahebi F, Somlo G, Rowley S, Vogl DT, Vesole DH, Pasquini M, Stadtmauer E. Tandem autologous-autologous versus autologous-allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma: Long-term follow-up results from the Blood and Marrow Transplant Clinical Trials Network 0102 trial. <i>Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation</i> . 2020 Apr 1; 26(4):798-804. doi:10.1016/j.bbmt.2019.11.018. Epub 2019 Nov 19.	BMT CTN 0102	PMC7198329

Number	Publication	Protocol Number	PMCID
112	Hourigan CS, Dillon LW, Gui G, Logan BR, Fei M, Ghannam J, Li Y, Licon A, Alyea EP, Bashey A, Deeg HJ, Devine SM, Fernandez HF, Giralt S, Hamadani M, Howard A, Maziarz RT, Porter DL, Scott BL, Warlick ED, Pasquini MC, Horwitz ME. Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease. <i>Journal of Clinical Oncology</i> . 2020 Apr 20; 38(12):1273-1283. doi:10.1200/JCO.19.03011. Epub 2019 Dec 20.	BMT CTN 0901	PMC7164487
2020			
113	Pidala J, Martens M, Anasetti C, Carreras J, Horowitz M, Lee SJ, Antin J, Cutler C, Logan B. Factors associated with successful discontinuation of immune suppression after allogeneic hematopoietic cell transplantation. <i>JAMA Oncology</i> . 2020 Jan 1; 6(1):e192974. doi: 10.1001/jamaoncol.2019.2974. Epub 2020 Jan 9.	BMT CTN 0201/0402	PMC6763979
114	Levine JE, Antin JH, Allen CE, Burroughs LM, Cooke KR, Devine S, Heslop H, Nakamura R, Talano JA, Yanik G, DiFronzo N. Priorities for improving outcomes for nonmalignant blood diseases: A report from the Blood and Marrow Transplant Clinical Trials Network. <i>Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation</i> . 2020 May 1; 26(5):e94-e100. doi: 10.1016/j.bbmt.2020.01.024. Epub 2020 Feb 5.	Network Publication	PMC8062984
115	Shah O, Tamaresis JS, Kenyon LJ, Xu L, Zheng P, Gupta P, Rangarajan K, Lee S, Spellman S, Nikiforow S, Zehnder J, Meyer EH. Analysis of the whole CDR3 T cell receptor repertoire after hematopoietic stem cell transplantation in 2 clinical cohorts. <i>Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation</i> . 2020 Jun 1; 26(6):1050-1070. doi:10.1016/j.bbmt.2020.01.020. Epub 2020 Feb 18.	BMT CTN 0802	PMC7503214
116	Costa LJ, Iacobelli S, Pasquini MC, Modi R, Giaccone L, Blade J, Schonland S, Evangelista A, Perez-Simon JA, Hari P, Brown EE, Giralt SA, Patriarca F, Stadtmauer EA, Rosinol L, Krishnan AY, Gahrton G, Bruno B. Long-term survival of 1338 MM patients treated with tandem autologous vs. autologous-allogeneic transplantation. <i>Bone Marrow Transplantation</i> . 2020 Sep 1; 55(9):1810-1816. doi:10.1038/s41409-020-0887-4. Epub 2020 Apr 14.	BMT CTN 0102	PMC7483973

Number	Publication	Protocol Number	PMCID
117	Holstein SA, Howard A, Avigan D, Bhutani M, Cohen AD, Costa LJ, Dhodapkar MV, Gay F, Gormley N, Green DJ, Hillengass J, Korde N, Li Z, Mailankody S, Neri P, Parekh S, Pasquini MC, Puig N, Roodman GD, Samur MK, Shah N, Shah UA, Shi Q, Spencer A, Suman VJ, Usmani SZ, McCarthy PL. Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network myeloma intergroup workshop on minimal residual disease and immune profiling. <i>Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation</i> . 2020 Oct 1; 26(10):e247-e255. doi:10.1016/j.bbmt.2020.06.011. Epub 2020 Jun 24.	Network Publication	PMC7529908
118	Costa LJ, Derman BA, Bal S, Sidana S, Chhabra S, Silbermann R, Ye JC, Cook G, Cornell RF, Holstein SA, Shi Q, Omel J, Callander NS, Chng WJ, Hungria V, Maiolino A, Stadtmauer E, Giralt S, Pasquini M, Jakubowiak AJ, Morgan GJ, Krishnan A, Jackson GH, Mohty M, Mateos MV, Dimopoulos MA, Facon T, Spencer A, Miguel JS, Hari P, Usmani SZ, Manier S, McCarthy P, Kumar S, Gay F, Paiva B. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. <i>Leukemia</i> . 2021 Jan 1; 35(1):18-30. doi:10.1038/s41375-020-01012-4. Epub 2020 Aug 11.	Network Publication	PubMed PMID: 32778736
119	Fuchs EJ, O'Donnell PV, Eapen M, Logan B, Antin JH, Dawson P, Devine S, Horowitz MM, Horwitz ME, Karanes C, Leifer E, Magenau JM, McGuirk JP, Morris LE, Rezvani AR, Jones RJ, Brunstein CG. Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: The BMT CTN 1101 trial. <i>Blood</i> . 2021 Jan 21; 137(3):420-428. doi:10.1182/blood.2020007535. Epub 2020 Aug 31.	BMT CTN 1101 PRIMARY MANUSCRIPT	PMC7819761
120	DeFilipp Z, Burns LJ, Jaglowski SM, Leppin AL, Pavletic S, Waldman B, Weisdorf DJ, Wood WA, Khera N. A new standard in graft-versus-host disease prophylaxis? An introduction to Blood and Marrow Transplant Clinical Trials Network 1703. <i>Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation</i> . 2020 Dec 1; 26(12):e305-e308. doi: 10.1016/j.bbmt.2020.08.029. Epub 2020 Sep 10.	BMT CTN 1703	PMC7735536
121	Farhadfar N, Burns LJ, Mupfudze T, Shaw BE, Bollard CM, Devine SM, Horowitz MM, Jones RJ, Murthy HS, Wingard JR, Lee SJ. Hematopoietic cell transplantation: Practice predictions for the year 2023. <i>Transplantation and Cellular Therapy</i> . 2021 Feb 1; 27(2):183.e1-183.e7. doi: 10.1016/j.bbmt.2020.10.006. Epub 2020 Oct 9.	Network Publication	PMC7546661

Number	Publication	Protocol Number	PMCID
122	Martens MJ, Logan BR. A unified approach to sample size and power determination for testing parameters in generalized linear and time-to-event regression models. <i>Statistics in Medicine</i> . 2021 Feb 28; 40(5):1121-1132. doi: 10.1002/sim.8823. Epub 2020 Nov 18.	BMT CTN 0402	PMC8020892
2021			
123	Devine SM, Horowitz MM. Building a fit for purpose clinical trials infrastructure to accelerate the assessment of novel hematopoietic cell transplantation strategies and cellular immunotherapies. <i>Journal of Clinical Oncology</i> . 2021 Feb 10; 39(5):534-544. doi: 10.1200/JCO.20.01623. Epub 2021 Jan 12.	Network Publication	PMC8443822
124	Dillon LW, Gui G, Logan BR, Fei M, Ghannam J, Li Y, Licon A, Alyea EP, Bashey A, Devine SM, Fernandez HF, Giralt S, Hamadani M, Howard A, Maziarz RT, Porter DL, Warlick ED, Pasquini MC, Scott BL, Horwitz ME, Deeg HJ, Hourigan CS. Impact of conditioning intensity and genomics on relapse after allogeneic transplantation for patients with myelodysplastic syndrome. <i>JCO Precision Oncology</i> . 2021 Jan 25; 5:PO.20.00355. doi: 10.1200/PO.20.00355.	BMT CTN 0901	PMC8140814
125	Reshef R, Saber W, Bolaños-Meade J, Chen G, Chen YB, Ho VT, Ponce DM, Nakamura R, Martens MJ, Hansen JA, Levine JE. Acute GVHD diagnosis and adjudication in a multicenter trial: A report from the BMT CTN 1202 biorepository study. <i>Journal of Clinical Oncology</i> . 2021 Jun 10; 39(17):1878-1887. doi: 10.1200/JCO.20.00619. Epub 2021 Jan 28.	BMT CTN 1202 PRIMARY MANUSCRIPT	PMC8260916
126	Scott BL, Pasquini MC, Fei M, Fraser R, Wu J, Devine SM, Porter DL, Maziarz RT, Warlick E, Fernandez HF, Soiffer RJ, Alyea E, Hamadani M, Bashey A, Giralt S, Geller NL, Leifer E, Hourigan CS, Gui G, Mendizabal A, Horowitz MM, Deeg HJ, Horwitz ME. Myeloablative versus reduced-intensity conditioning for hematopoietic cell transplantation in acute myelogenous leukemia and myelodysplastic syndromes-long-term follow-up of the BMT CTN 0901 Clinical Trial. <i>Transplantation and Cellular Therapy</i> . 2021 Jun 1; 27(6):483.e1-483.e6. doi: 10.1016/j.jtct.2021.02.031. Epub 2021 Feb 26.	BMT CTN 0901	PMC8217373
127	Kim HT, Logan B, Weisdorf DJ. Novel composite endpoints after allogeneic hematopoietic cell transplantation. <i>Transplantation and Cellular Therapy</i> . 2021 Aug 1; 27(8):650-657. doi: 10.1016/j.jtct.2021.05.005. Epub 2021 May 15.	BMT CTN 1203 and 1301	PMC8489461

Number	Publication	Protocol Number	PMCID
128	Holstein SA, Bahlis N, Bergsagel PL, Bhutani M, Bolli N, Brownstein C, Demolis P, Foureau D, Gay F, Ghobrial IM, Gormley N, Hillengass J, Kaiser M, Maus MV, Melenhorst JJ, Merz M, Dwyer MO, Paiva B, Pasquini MC, Shah N, Wong SW, Usmani SZ, McCarthy PL. The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma. Transplantation and Cellular Therapy. 2021 Oct 1; 27(10):807-816. doi: 10.1016/j.jtct.2021.05.027. Epub 2021 Jun 6.	Network Publication	PMC8478786
129	Nakamura R, Saber W, Martens MJ, Ramirez A, Scott B, Oran B, Leifer E, Tamari R, Mishra A, Maziarz RT, McGuirk J, Westervelt P, Vasu S, Patnaik M, Kamble R, Forman SJ, Sekeres MA, Appelbaum F, Mendizabal A, Logan B, Horowitz M, Cutler C. Biologic assignment trial of reduced-intensity hematopoietic cell transplantation based on donor availability in patients 50-75 years of age with advanced myelodysplastic syndrome. Journal of Clinical Oncology. 2021 Oct 20; 39(30):3328-3339. doi: 10.1200/JCO.20.03380. Epub 2021 Jun 9.	BMT CTN 1102 PRIMARY MANUSCRIPT	PMC8791814
130	Brunstein CG, DeFor TE, Fuchs EJ, Karanes C, McGuirk JP, Rezvani AR, Eapen M, O'Donnell PV, Weisdorf DJ; Blood and Marrow Transplant Clinical Trials Network. Engraftment of double cord blood transplantation after nonmyeloablative conditioning with escalated total body irradiation dosing to facilitate engraftment in immunocompetent patients. Transplantation and Cellular Therapy. 2021 Oct 1; 27(10):879.e1-879.e3. doi: 10.1016/j.jtct.2021.07.006. Epub 2021 Jul 15.	BMT CTN 1101	PMC8858593
131	Tilley BC, Mainous AG 3rd, Amorrortu RP, McKee MD, Smith DW, Li R, DeSantis SM, Vernon SW, Koch G, Ford ME, Diaz V, Alvidrez J; additional RECRUIT Trial Center and Parent Trials' investigators. Using increased trust in medical researchers to increase minority recruitment: The RECRUIT cluster randomized clinical trial. Contemporary Clinical Trials. 2021 Oct 1; 109:106519. doi: 10.1016/j.cct.2021.106519. Epub 2021 Jul 30.	BMT CTN 1505 PRIMARY MANUSCRIPT	PMC8665835
132	Warlick ED, Ustun C, Andreescu A, Bonagura AF, Brunner A, Chandra AB, Foran JM, Juckett MB, Kindwall-Keller TL, Klimek VM, Pease DF, Steensma DP, Waldman BM, Horowitz MM, Burns LJ, Khera N. Blood and Marrow Transplant Clinical Trials Network study 1102 heralds a new era in hematopoietic cell transplantation in high-risk myelodysplastic syndromes: Challenges and opportunities in implementation. Cancer. 2021 Dec 1; 127(23):4339-4347. doi: 10.1002/cncr.33826. Epub 2021 Aug 10.	BMT CTN 1102	PMC8578257

Number	Publication	Protocol Number	PMCID
133	Heslop HE, Stadtmauer EA, Levine JE, Ballen KK, Chen YB, DeZern AE, Eapen M, Hamadani M, Hamilton BK, Hari P, Jones RJ, Logan BR, Kean LS, Leifer ES, Locke FL, Maziarz RT, Nemecek ER, Pasquini M, Phelan R, Riches ML, Shaw BE, Walters MC, Foley A, Devine SM, Horowitz MM. Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking forward as the network celebrates its 20th year. Transplantation and Cellular Therapy. 2021 Nov 1; 27(11):885-907. doi: 10.1016/j.jtct.2021.08.016. Epub 2021 Aug 27.	Network Publication	PMC8556300
134	Shindiapina P, Pietrzak M, Seweryn M, McLaughlin E, Zhang X, Makowski M, Ahmed EH, Schlotter S, Pearson R, Kitzler R, Mozhenkova A, Le-Rademacher J, Little RF, Akpek G, Ayala E, Devine SM, Kaplan LD, Noy A, Popat UR, Hsu JW, Morris LE, Mendizabal AM, Krishnan A, Wachsman W, Williams N, Sharma N, Hofmeister CC, Forman SJ, Navarro WH, Alvarnas JC, Ambinder RF, Lozanski G, Baiocchi RA. Immune recovery following autologous hematopoietic stem cell transplantation in HIV-related lymphoma patients on the BMT CTN 0803/AMC 071 trial. Frontiers in Immunology. 2021 Sep 3; 12:700045. doi: 10.3389/fimmu.2021.700045.	BMT CTN 0803	PMC8446430
135	Wingard JR, Alexander BD, Baden LR, Chen M, Sugrue MW, Leather HL, Caliendo AM, Clancy CJ, Denning DW, Marty FM, Nguyen MH, Wheat LJ, Logan BR, Horowitz MM, Marr KA. Impact of changes of the 2020 consensus definitions of invasive aspergillosis on clinical trial design: Unintended consequences for prevention trials? Open Forum Infectious Diseases. 2021 Sep 9; 8(10):ofab441. doi: 10.1093/ofid/ofab441.	BMT CTN 0101	PMC8496761
136	O'Donnell PV, Brunstein CG, Fuchs EJ, Zhang MJ, Allbee-Johnson M, Antin JH, Leifer ES, Elmariah H, Grunwald MR, Hashmi H, Horowitz MM, Magenau JM, Majhail N, Milano F, Morris LE, Rezvani AR, McGuirk JP, Jones RJ, Eapen M. Umbilical cord blood or HLA-haploidentical transplantation: Real-world outcomes versus randomized trial outcomes. Transplantation and Cellular Therapy. 2022 Feb 1; 28(2):109.e1-109.e8. doi: 10.1016/j.jtct.2021.11.002. Epub 2021 Nov 11.	BMT CTN 1101	PMC8882346
137	Meyers G, Hamadani M, Martens M, Ali H, Choe H, Dawson P, Harris AC, van Hooren E, Klaassen W, Leifer E, MacMillan ML, van Oosterhout Y, Perez L, Pusic I, Vo P, Levine JE. Lessons learned from early closure of a clinical trial for steroid-refractory acute GVHD. Bone Marrow Transplantation. 2022 Feb 1; 57(2):302-303. doi: 10.1038/s41409-021-01529-x. Epub 2021 Nov 23.	BMT CTN 1802 PRIMARY MANUSCRIPT	PMC8825705

Number	Publication	Protocol Number	PMCID
138	Luznik L, Pasquini MC, Logan B, Soiffer RJ, Wu J, Devine SM, Geller N, Giralto S, Heslop HE, Horowitz MM, Jones RJ, Litzow MR, Mendizabal A, Muffy L, Nemecek ER, O'Donnell L, O'Reilly RJ, Palencia R, Schetelig J, Shune L, Solomon SR, Vasu S, Ho VT, Perales MA. Randomized Phase III BMT CTN trial of calcineurin inhibitor-free chronic graft-versus-host disease interventions in myeloablative hematopoietic cell transplantation for hematologic malignancies. <i>Journal of Clinical Oncology</i> . 2022 Feb 1; 40(4):356-368. doi: 10.1200/JCO.21.02293. Epub 2021 Dec 2.	BMT CTN 1301 PRIMARY MANUSCRIPT	PMC8797487
2022			
139	Dispenzieri A, Krishnan A, Arendt B, Blackwell E, Wallace P, Dasari S, Vogl D, Efebera Y, Fei M, Geller N, Giralto S, Hahn T, Howard A, Kohlhagen M, Landau H, Hari P, Pasquini MC, Qazilbash M, McCarthy P, Shah N, Vesole D, Stadtmauer E, Murray D. Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT). <i>Blood Cancer Journal</i> . 2022 Feb 10; 12(2):27. doi:10.1038/s41408-022-00624-6.	BMT CTN 0702/07LT	PMC8831597
140	Castro-Pearson S, Le CT, Luo X. Two-sample survival probability curves: A graphical approach for the analysis of time to event data in clinical trials. <i>Contemporary Clinical Trials</i> . 2022 Apr 1; 115:106707. doi: 10.1016/j.cct.2022.106707. Epub 2022 Feb 14.	BMT CTN 0201	PMC9018539
141	Brunstein CG, O'Donnell PV, Logan B, Dawson P, Costa L, Cutler C, Craig M, Hogan W, Horowitz MM, Horwitz ME, Karanes C, Magenau JM, Malone A, McCarty J, McGuirk JP, Morris LE, Rezvani AR, Salit R, Vasu S, Eapen M, Fuchs EJ; Blood and Marrow Transplant Clinical Trials Network. Impact of center experience with donor type on outcomes: A secondary analysis, Blood and Marrow Transplant Clinical Trials Network 1101. <i>Transplantation and Cellular Therapy</i> . 2022 Apr 4; S2666-6367(22)01189-7. doi: 10.1016/j.jtct.2022.03.024. Epub 2022 Apr 4.	BMT CTN 1101	PMC9253061

Number	Publication	Protocol Number	PMCID
142	Thanarajasingam G, Minasian LM, Bhatnagar V, Cavalli F, De Claro RA, Dueck AC, El-Galaly TC, Everest N, Geissler J, Gisselbrecht C, Gormley N, Gribben J, Horowitz M, Ivy SP, Jacobson CA, Keating A, Kluetz PG, Kwong YL, Little RF, Matasar MJ, Mateos MV, McCullough K, Miller RS, Mohty M, Moreau P, Morton LM, Nagai S, Nair A, Nastoupil L, Robertson K, Sidana S, Smedby KE, Sonneveld P, Tzoganis K, van Leeuwen FE, Velikova G, Villa D, Wingard JR, Seymour JF, Habermann TM. Reaching beyond maximum grade: Progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies. <i>The Lancet Haematology</i> . 2022 May 1; 9(5):e374-e384. doi: 10.1016/S2352-3026(22)00045-X.	Network Publication	PMC9241484
143	Hamilton BK, Cutler C, Divine C, Juckett M, LeMaistre C, Stewart S, Wilder J, Horowitz M, Khera N, Burns LJ. Are we making PROGRESS in preventing graft-versus-host disease and improving clinical outcomes? Impact of BMT CTN 1301 study results on clinical practice. <i>Transplantation and Cellular Therapy</i> . 2022 Aug 1; 28(8):419-425. doi: 10.1016/j.jtct.2022.05.002. Epub 2022 May 9.	BMT CTN 1301	PMC9364468
144	Holstein SA, Asimakopoulos F, Azab AK, Bianchi G, Bhutani M, Crews LA, Cupedo T, Giles H, Gooding S, Hillengass J, John L, Kaiser S, Lee L, MacLachlan K, Pasquini MC, Pichiorri F, Shah N, Shokeen M, Shy BR, Smith EL, Verona R, Usmani SZ, McCarthy PL. Proceedings from the Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on immune and cellular therapy in multiple myeloma. <i>Transplantation and Cellular Therapy</i> . 2022 Aug 1; 28(8):446-454. doi: 10.1016/j.jtct.2022.05.019. Epub 2022 May 21.	Network Publication	PMC9357156
145	D'Souza A, Brazauskas R, Stadtmauer EA, Pasquini MC, Hari P, Bashey A, Callander N, Devine S, Efebera Y, Ganguly S, Gasparetto C, Geller N, Horowitz MM, Koreth J, Landau H, Brunstein C, McCarthy P, Qazilbash MH, Giral S, Krishnan A, Flynn KE. Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma. <i>American Journal of Hematology</i> . 2023 Jan 1; 98(1):140-147. doi: 10.1002/ajh.26596. Epub 2022 May 21.	BMT CTN 0702	PMC9659666

Number	Publication	Protocol Number	PMCID
146	Richardson PG, Jacobus SJ, Weller EA, Hassoun H, Lonial S, Raje NS, Medvedova E, McCarthy PL, Libby EN, Voorhees PM, Orlowski RZ, Anderson LD Jr, Zonder JA, Milner CP, Gasparetto C, Agha ME, Khan AM, Hurd DD, Gowin K, Kamble RT, Jagannath S, Nathwani N, Alsina M, Cornell RF, Hashmi H, Campagnaro EL, Andreescu AC, Gentile T, Liedtke M, Godby KN, Cohen AD, Openshaw TH, Pasquini MC, Giralta SA, Kaufman JL, Yee AJ, Scott E, Torka P, Foley A, Fulciniti M, Hebert K, Samur MK, Masone K, Maglio ME, Zeytoonjian AA, Nadeem O, Schlossman RL, Laubach JP, Paba-Prada C, Ghobrial IM, Perrot A, Moreau P, Avet-Loiseau H, Attal M, Anderson KC, Munshi NC; DETERMINATION investigators. Triplet therapy, transplantation, and maintenance until progression in myeloma. The New England Journal of Medicine. 2022 Jul 14; 387(2):132-147. doi: 10.1056/NEJMoa2204925. Epub 2022 Jun 5.	BMT CTN 1304 PRIMARY MANUSCRIPT	PMC10040899
147	Farhadfar N, Ahn KW, Bo-Subait S, Logan B, Stefanski HE, Hsu JW, Panch S, Confer D, Liu H, Badawy SM, Beitinjaneh A, Diaz MA, Hildebrandt GC, Kelkar AH, Lazarus HM, Murthy HS, Preussler JM, Schears RM, Sharma A, van der Poel M, Bruce JG, Pulsipher MA, Shaw BE, Wingard JR, Switzer GE. The impact of pre-apheresis health related quality of life on peripheral blood progenitor cell yield and donor's health and outcome: Secondary analysis of patient-reported outcome data from the RDSafe and BMT CTN 0201 Clinical Trials. Transplantation and Cellular Therapy. 2022 Jun 7: S2666-6367(22)01361-6. doi: 10.1016/j.jtct.2022.05.042. Epub 2022 Jun 7.	BMT CTN 0201	PMC9427696
148	Bashir Q, Nishihori T, Pasquini MC, Martens MJ, Wu J, Alsina M, Anasetti C, Brunstein C, Dawson P, Efebera Y, Gasparetto C, Geller N, Giralta S, Hall AC, Koreth J, McCarthy P, Scott E, Stadtmauer EA, Vesole DH, Hari P. A multicenter Phase II, double-blind placebo-controlled trial of maintenance ixazomib after allogeneic transplantation for high-risk multiple myeloma: Results of the Blood and Marrow Transplant Clinical Trials Network 1302 Trial. Transplantation and Cellular Therapy. 2023 June 1: S2666-6367(22)01467-1. doi: 10.1016/j.jtct.2022.07.007. Epub 2022 July 12.	BMT CTN 1302 PRIMARY MANUSCRIPT	PMC10442072

Number	Publication	Protocol Number	PMCID
149	DeZern AE, Eapen M, Wu J, Talano JA, Solh M, Dávila Saldaña BJ, Karanes C, Horwitz ME, Mallhi K, Arai S, Farhadfar N, Hexner E, Westervelt P, Antin JH, Deeg HJ, Leifer E, Brodsky RA, Logan BR, Horowitz MM, Jones RJ, Pulsipher MA. Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): A multicentre, single-arm, Phase 2 trial. The Lancet Haematology. 2022 Sep 1; 9(9):e660-e669. doi: 10.1016/S2352-3026(22)00206-X. Epub 2022 Jul 27. Erratum in: Lancet Haematology. 2022 Sep 1; 9(9):e641.	BMT CTN 1502 PRIMARY MANUSCRIPT	PMC9444987
150	Lai TP, Verhulst S, Dagnall CL, Hutchinson A, Spellman SR, Howard A, Katki HA, Levine JE, Saber W, Aviv A, Gadalla SM. Decoupling blood telomere length from age in recipients of allogeneic hematopoietic cell transplant in the BMT-CTN 1202. Frontiers in Immunology. 2022 Oct 3; 13:966301. doi: 10.3389/fimmu.2022.966301.	BMT CTN 1202	PMC9574912
151	Krishnamurti L, Neuberg D, Sullivan KM, Smith S, Eapen M, Walters MC. Enrollment lessons from a biological assignment study of marrow transplantation versus standard care for adolescents and young adults with sickle cell disease: Considerations for future gene and cellular therapy trials. Transplantation and Cellular Therapy. 2023 Apr 1;29(4):217-221. doi: 10.1016/j.jtct.2022.10.008. Epub 2022 Oct 18.	BMT CTN 1503	PMC10539686
152	Vasu S, Holtan SG, Shimamura A, Burnworth T, Whisenton S, Adams S, Nuechterlein B, Mortier N, Foster J, DiFronzo N, Horowitz M, Rizzo D, Foley A. Bringing patient and caregivers voices to the clinical trial chorus: A report from the BMT CTN Patient and Caregiver Advocacy Task Force. Transplantation and Cellular Therapy. 2023 Jan 1; 29(1):5-9. doi: 10.1016/j.jtct.2022.10.016. Epub 2022 Oct 23.	Network Publication	PMC10008748
153	Cusatis R, Martens MJ, Nakamura R, Cutler CS, Saber W, Lee SJ, Logan BR, Shaw BE, Gregory A, D'Souza A, Hamilton BK, Horowitz MM, Flynn KE. Health-related quality of life in reduced intensity hematopoietic cell transplantation based on donor availability in patients aged 50-75 with advanced myelodysplastic syndrome: BMT CTN 1102. American Journal of Hematology. 2023 Feb 1; 98(2):229-250. doi: 10.1002/ajh.26768. Epub 2022 Nov 21.	BMT CTN 1102	PMC9839494

Number	Publication	Protocol Number	PMCID
154	Putta S, Young BA, Levine JE, Reshef R, Nakamura R, Strouse C, Perales MA, Howard A, Pine P, Shi J, Zhang P, Ho VT, Saber W. Prognostic biomarkers for hepatic veno-occlusive disease/sinusoidal obstruction syndrome in myeloablative allogeneic hematopoietic cell transplantation: Results from the Blood and Marrow Transplant Clinical Trials Network 1202 study. Transplantation and Cellular Therapy. 2023 Mar 1; 29(3): 166.e1-166.e10. doi: 10.1016/j.jtct.2022.11.024. Epub 2022 Nov 28.	BMT CTN 1202	PMC10116945
2023			
155	Juckett M, Dandoy C, DeFilipp Z, Kindwall-Keller TL, Spellman SR, Ustun C, Waldman BM, Weisdorf DJ, Wood WA, Horowitz MM, Burns LJ, Khera N. How do we improve the translation of new evidence into the practice of hematopoietic cell transplantation and cellular therapy? Blood Reviews. 2023 Jul 1; 60:101079. doi: 10.1016/j.blre.2023.101079. Epub 2023 Apr 7.	Network Publication	PMC10330269
156	Geerlinks AV, Scull B, Krupski C, Fleischmann R, Pulsipher MA, Eapen M, Connelly JA, Bollard CM, Pai SY, Duncan C, Kean LS, Baker KS, Burroughs L, Andolina JR, Shenoy S, Roehrs P, Hanna R, Talano JA, Schultz KR, Stenger EO, Lin H, Zoref-Lorenz A, McClain KL, Jordan MB, Man TK, Allen CE, Marsh RA. Alemtuzumab and CXCL9 levels predict likelihood of sustained engraftment after reduced intensity conditioning HCT. Blood Advances. 2023 Jul 25; bloodadvances.2022009478. doi: 10.1182/bloodadvances.2022009478. Epub 2023 Apr 12.	BMT CTN 1204	PMC10368780
157	Jurdi NE, Martens MJ, Brunstein CG, O'Donnell P, Lee SJ, D'Souza A, Logan B, Hong S, Singh AK, Sandhu K, Shapiro RM, Horowitz MM, Hamilton BK. Health-related quality of life in double umbilical cord blood vs. haploidentical marrow transplantation: A QOL analysis report of BMT CTN 1101. Transplantation and Cellular Therapy. 2023 Jul 1; 29(7):467.e1-467.e5. doi: 10.1016/j.jtct.2023.04.009. Epub 2023 Apr 22.	BMT CTN 1101	PMC10330136
158	Ramsey SD, Bansal A, Li L, O'Donnell PV, Fuchs EJ, Brunstein CG, Eapen M, Thao V, Roth JA, Steuten L. Cost-effectiveness of unrelated umbilical cord blood vs. HLA haploidentical related bone marrow transplant: Evidence from BMT CTN 1101. Transplantation and Cellular Therapy. 2023 Jul 1; 29(7):464.e1-464.e8. doi: 10.1016/j.jtct.2023.04.017. Epub 2023 Apr 27.	BMT CTN 1101	PMC10353308

Number	Publication	Protocol Number	PMCID
159	Hill JA, Martens MJ, Young JH, Bhavsar K, Kou J, Chen M, Lee LW, Baluch A, Dhodapkar MV, Nakamura R, Peyton K, Shahid Z, Armistead P, Westervelt P, McCarty J, McGuirk J, Hamadani M, DeWolf S, Hosszu K, Sharon E, Spahn A, Toor AA, Waldvogel S, Greenberger LM, Auletta JJ, Horowitz MM, Riches ML, Perales MA. SARS-CoV-2 vaccination in the first year after allogeneic hematopoietic cell transplant: A prospective, multicentre, observational study. <i>EClinicalMedicine</i> . 2023 May 1; 59:101983. doi: 10.1016/j.eclinm.2023.101983. Epub 2023 Apr 27.	BMT CTN 2101 PRIMARY MANUSCRIPT	PMC10133891
160	Mohan M, Janz S, Brazauskas R, Dwinell MB, Teng BQ, Yun G, Dong J, Pasquini MC, Giralt S, Landau H, Stadtmauer E, Krishnan A, D'Souza A. Increased CXCL10 is seen at 1-year after autologous hematopoietic cell transplantation in multiple myeloma patients on maintenance lenalidomide therapy. <i>Bone Marrow Transplantation</i> . 2023 Aug;58(8):953-955. doi: 10.1038/s41409-023-02004-5. Epub 2023 May 6.	BMT CTN 0702	PMC10555486
161	Martens MJ, Gao Y, Szabo A. Designing and conducting a clinical trial in blood and marrow transplantation. <i>Best Practice and Research Clinical Haematology</i> . 2023 Jun;36(2):101471. doi: 10.1016/j.beha.2023.101471. Epub 2023 May 11.	Network Publication	PMC10845212
162	Bolaños-Meade J, Hamadani M, Wu J, Al Malki MM, Martens MJ, Runaas L, Elmariah H, Rezvani AR, Gooptu M, Larkin KT, Shaffer BC, El Jurdi N, Loren AW, Solh M, Hall AC, Alousi AM, Jamy OH, Perales MA, Yao JM, Applegate K, Bhatt AS, Kean LS, Efebera YA, Reshef R, Clark W, DiFronzo NL, Leifer E, Horowitz MM, Jones RJ, Holtan SG; BMT CTN 1703 Investigators. Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis. <i>New England Journal of Medicine</i> . 2023 Jun 22; 388(25):2338-2348. doi: 10.1056/NEJMoa2215943.	BMT CTN 1703 PRIMARY MANUSCRIPT	PMC10575613
163	Martens MJ, Kim S, Ahn KW. Sample size and power determination for multiparameter evaluation in nonlinear regression models with potential stratification. <i>Biometrics</i> . 2023 Dec;79(4):3916-3928. doi: 10.1111/biom.13897. Epub 2023 Jun 25.	Network Publication	PMC10749377

Number	Publication	Protocol Number	PMCID
164	Chung DJ, Shah N, Wu J, Logan B, Bisharat L, Callander N, Cheloni G, Anderson K, Chodon T, Dhakal B, Devine S, Somaiya Dutt P, Efebera Y, Geller N, Ghiasuddin H, Hematti P, Holmberg L, Howard A, Johnson B, Karagkouni D, Lazarus HM, Malek E, McCarthy P, McKenna D, Mendizabal A, Nooka A, Munshi N, O'Donnell L, Rapoport AP, Reese J, Rosenblatt J, Soiffer R, Stroopinsky D, Uhl L, Vlachos IS, Waller EK, Young JW, Pasquini MC, Avigan D. Randomized trial of a personalized dendritic cell vaccine after autologous stem cell transplant for multiple myeloma: BMT CTN 1401. <i>Clinical Cancer Research</i> . 2023 Dec 1; 29(23):4784-4796. doi: 10.1158/1078-0432.CCR-23-0235. Epub 2023 Jul 18.	BMT CTN 1401 PRIMARY MANUSCRIPT	PMC10690096
165	Gillis N, Padron E, Wang T, Chen K, DeVos JD, Spellman SR, Lee SJ, Kitko CL, MacMillan ML, West J, Tang YH, Teng M, McNulty S, Druley TE, Pidala JA, Lazaryan A. Pilot study of donor-engrafted clonal hematopoiesis evolution and clinical outcomes in allogeneic hematopoietic cell transplantation recipients using a national registry. <i>Transplantation and Cellular Therapy</i> . 2023 Oct 1; 29(10):640.e1-640.e8. doi: 10.1016/j.jtct.2023.07.021. Epub 2023 Jul 28.	BMT CTN 1202	PMC10592088
166	Logan BR, Fu D, Howard A, Fei M, Kou J, Little MR, Adom D, Mohamed FA, Blazar BR, Gaffken PR, Paczesny S. Validated graft-specific biomarkers identify patients at risk for chronic graft-versus-host disease and death. <i>The Journal of Clinical Investigation</i> . 2023 Aug 1; 133(15):e168575. doi: 10.1172/JCI168575. Epub 2023 Aug 1.	BMT CTN 0201 and 1202	PMC10378149
167	Versluis J, Saber W, Tsai HK, Gibson CJ, Dillon LW, Mishra A, McGuirk J, Maziarz RT, Westervelt P, Hegde P, Mukherjee D, Martens MJ, Logan B, Horowitz M, Hourigan CS, Nakamura R, Cutler C, Lindsley RC; Blood and Marrow Transplant Clinical Trials Network. Allogeneic hematopoietic cell transplantation improves outcome in myelodysplastic syndrome across high-risk genetic subgroups: Genetic analysis of the Blood and Marrow Transplant Clinical Trials Network 1102 Study. <i>Journal of Clinical Oncology</i> . 2023 Oct 1; 41(28):4497-4510. doi: 10.1200/JCO.23.00866. Epub 2023 Aug 22.	BMT CTN 1102	PMC10552956

Number	Publication	Protocol Number	PMCID
168	Meyers G, Hamadani M, Martens M, Ali H, Chevallier P, Choe H, Harris AC, Holler E, van Hooren E, Klaassen W, Leifer E, van Oosterhout Y, Perez L, Pusic I, Stelljes M, van der Velden W, Ammatuna E, Beauvais D, Cornillon J, Maziarz RT, Schetelig J, Romeril J, MacMillan ML, Levine JE, Socié G. Anti-CD3/CD7 immunoconjugate (T-Guard) for severe, steroid-refractory GVHD: Final report of BMT CTN 2002. Bone Marrow Transplantation. 2023 Dec; 58(12):1416-1418. doi: 10.1038/s41409-023-02110-4. Epub 2023 Sep 25.	BMT CTN 2002 PRIMARY MANUSCRIPT	PMC11732251
169	Martens MJ, Logan BR. Statistical rules for safety monitoring in clinical trials. Clinical Trials. 2024 Apr 1; 21(2):152-161. doi: 10.1177/17407745231203391. Epub 2023 Oct 25.	Network Publication	PMC11003847
170	McCarthy PL, Attwood KM, Liu X, Chen GL, Minderman H, Alousi A, Bashey A, Lowsky R, Miklos DB, Hansen J, Westervelt P, Yanik G, Waller EK, Howard A, Blazar BR, Wallace PK, Reshef R, Horowitz MM, Maziarz RT, Levine JE, Mohammadpour H. Galectin-3 predicts acute GvHD and overall mortality post reduced intensity allo-HCT: A BMT-CTN biorepository study. Bone Marrow Transplantation. 2024 Mar 1; 59(3):334-343. doi: 10.1038/s41409-023-02168-0. Epub 2023 Dec 18.	BMT CTN 1202	PMC10961739
2024			
171	Malek E, Kort J, Metheny L, Fu P, Hari P, Efebera Y, Callander NS, Qazilbash MH, Giral S, Krishnan A, Stadtmauer EA, Lazarus HM. Impact of visceral obesity on clinical outcome and quality of life for patients with multiple myeloma: A secondary data analysis of STaMINA (BMT CTN 0702) trial. Transplantation and Cellular Therapy. 2024 Jul;30(7):698.e1-698.e10. doi: 10.1016/j.jtct.2024.01.053. Epub 2024 Jan 19.	BMT CTN 0702	PMC12175559
172	Shaw BE, Flynn KE, He N, Cusatis R, D'Souza A, Hamilton BK, Horowitz MM, Mattila D, Phelan R, Lee SJ, Brazauskas R. Incorporating patient-reported outcome data into a predictive calculator for allogeneic hematopoietic cell transplantation recipients. Cancer. 2024 May 15;130(10):1826-1835. doi: 10.1002/cncr.35189. Epub 2024 Jan 10.	Network Publication	PMC11058023
173	Saber W, Bansal A, Li L, Scott BL, Sangaralingham LR, Thao V, Roth JA, Wright W, Steuten LMG, Pidala JA, Mishra A, Maziarz RT, Westervelt P, McGuirk JP, Cutler C, Nakamura R, Ramsey SD. Cost-effectiveness of reduced-intensity allogeneic hematopoietic cell transplantation for older patients with high-risk myelodysplastic syndrome: Analysis of BMT CTN 1102. JCO Oncology Practice. 2024 Apr 1;20(4):572-580. doi: 10.1200/OP.23.00413. Epub 2024 Jan 23.	BMT CTN 1102	PMC11648677

Number	Publication	Protocol Number	PMCID
174	Eapen M, Kou J, Andreansky M, Bhatia M, Brochstein J, Chaudhury S, Haight AE, Haines H, Jacobsohn D, Jaroscak J, Kasow KA, Krishnamurti L, Levine JE, Leung K, Margolis D, Yu LC, Horowitz MM, Kamani N, Walters MC, Shenoy S. Long-term outcomes after unrelated donor transplantation for severe sickle cell disease on the BMT CTN 0601 trial. American journal of hematology. 2024 Apr 1; 99(4):785-788. doi: 10.1002/ajh.27251. Epub 2024 Feb 11.	BMT CTN 0601	PMC10947844
175	Brazauskas R, Flynn K, Krishnan A, Landau H, Giralt S, Pasquini MC, Stadtmauer EA, D'Souza A. Symptom clusters and their impact on quality of life in multiple myeloma survivors: Secondary analysis of BMT CTN 0702 trial. British Journal of Haematology. 2024 Apr 1; 204(4):1429-1438. doi: 10.1111/bjh.19326. Epub 2024 Feb 13.	BMT CTN 0702	PMC11006567
176	Shahid Z, Etra AM, Levine JE, Riches ML, Baluch A, Hill JA, Nakamura R, Toor AA, Ustun C, Young JH, Perales MA, Epstein DJ, Murthy HS. Defining and grading infections in clinical trials involving hematopoietic cell transplantation: A report from the BMT CTN infectious disease technical committee. Transplantation and Cellular Therapy. 2024 May 1; 30(5):540.e1-540.e13. doi: 10.1016/j.jtct.2024.03.001. Epub 2024 Mar 6.	Network Publication	PMC11217895
177	Levis MJ, Hamadani M, Logan B, Jones RJ, Singh AK, Litzow M, Wingard JR, Papadopoulos EB, Perl AE, Soiffer RJ, Ustun C, Ueda Oshima M, Uy GL, Waller EK, Vasu S, Solh M, Mishra A, Muffly L, Kim HJ, Mikesch JH, Najima Y, Onozawa M, Thomson K, Nagler A, Wei AH, Marcucci G, Geller NL, Hasabou N, Delgado D, Rosales M, Hill J, Gill SC, Nuthethi R, King D, Wittsack H, Mendizabal A, Devine SM, Horowitz MM, Chen YB; BMT-CTN 1506/MORPHO Study Investigators. Gilteritinib as post-transplant maintenance for acute myeloid leukemia with internal tandem duplication mutation of <i>FLT3</i> . Journal of Clinical Oncology. 2024 May 20; 42(15):1766-1775. doi: 10.1200/JCO.23.02474. Epub 2024 Mar 12.	BMT CTN 1506 PRIMARY MANUSCRIPT	PMC11095884
178	Pasquini MC, Wallace PK, Logan B, Kaur M, Tario JD, Howard A, Zhang Y, Brunstein C, Efebera Y, Geller N, Giralt S, Hari P, Horowitz MM, Koreth J, Krishnan A, Landau H, Somlo G, Shah N, Stadtmauer E, Vogl DT, Vesole DH, McCarthy PL, Hahn T. Minimal residual disease status in multiple myeloma 1 year after autologous hematopoietic cell transplantation and lenalidomide maintenance are associated with long-term overall survival. Journal of Clinical Oncology. 2024 Aug 10; 42(23):2757-2768. doi: 10.1200/JCO.23.00934. Epub 2024 May 3.	BMT CTN 0702	PMC11634105

Number	Publication	Protocol Number	PMCID
179	Hill JA, Martens MJ, Young JH, Bhavsar K, Kou J, Chen M, Lee LW, Baluch A, Dhodapkar MV, Nakamura R, Peyton K, Howard DS, Ibrahim U, Shahid Z, Armistead P, Westervelt P, McCarty J, McGuirk J, Hamadani M, DeWolf S, Hosszu K, Sharon E, Spahn A, Toor AA, Waldvogel S, Greenberger LM, Auletta JJ, Horowitz MM, Riches ML, Perales MA. SARS-CoV-2 vaccination in the first year after hematopoietic cell transplant or chimeric antigen receptor T cell therapy: A prospective, multicenter, observational study. <i>Clinical Infectious Diseases</i> . 2024 Aug 16;79(2):542-554. doi: 10.1093/cid/ciae291. Epub 2024 May 27.	BMT CTN 2101 PRIMARY MANUSCRIPT	PMC11327798
180	Levis MJ, Hamadani M, Horowitz MM, Chen YB. Reply to S. Fuji / How could we further improve the gilteritinib maintenance after allogeneic hematopoietic cell transplantation in FLT3-mutated AML? <i>Journal of Clinical Oncology</i> . 2024 Nov 10;42(32):3881-3882. doi: 10.1200/JCO.24.01091. Epub 2024 Jul 31.	BMT CTN 1506	PMC11540746
181	Hamilton BK, Pandya BJ, Ivanescu C, Elsouda D, Hamadani M, Chen YB, Levis MJ, Ueda Oshima M, Litzow MR, Soiffer RJ, Ustun C, Perl AE, Singh AK, Geller NL, Hasabou N, Rosales M, Cella D, Corredoira L, Pestana C, Horowitz MM, Logan BR. Health-related quality of life with gilteritinib versus placebo post-transplant for FLT3-ITD+ acute myeloid Leukemia. <i>Blood Advances</i> . 2024 Oct 8; 8(19):5091-5099. doi: 10.1182/bloodadvances.2024013746. Epub 2024 Aug 21.	BMT CTN 1506	PMC11460446
182	Newell LF, El Jurdi N, Betts BC, Cutler C, Antin JH, Levine JE, Panoskaltsis-Mortari A, Holtan SG. Vascular biomarkers reveal a unique toxicity profile of posttransplant cyclophosphamide: Secondary analysis of BMT CTN 0402 and 1202. <i>Blood Vessels, Thrombosis & Hemostasis</i> 2024; 1 (3): 100020. doi: doi.10.1016/j.bvth.2024.100020. Epub 2024 Jul 26.	BMT CTN 0402 and 1202	PMC12158423
183	Eapen M, Antin JH, Tolar J, Arai S, Horwitz ME, Kou J, Leifer E, McCarty JM, Nakamura R, Pulsipher MA, Rowley SD, Horowitz MM, Deeg HJ. Long-term survival after unrelated donor marrow transplantation for aplastic anaemia after optimized conditioning regimen: A retrospective multicentre cohort study. <i>EClinicalMedicine</i> . 2024 Sep 5; 76:102819. doi: 10.1016/j.eclim.2024.102819. eCollection 2024 Oct.	BMT CTN 0301	PMC11405822
184	John TD, Walters MC, Rangarajan HG, Rahim MQ, McKinney CM, Bollard CM, Abusin G, Eapen M, Kassim AA, DeBaun MR. Incremental eligibility criteria for the BMT CTN 1507 haploidentical trial for children with sickle cell disease. <i>Blood Advances</i> . 2024 Dec 10; 8(23):6055-6063. doi: 10.1182/bloodadvances.2024014078. Epub 2024 Oct 7.	BMT CTN 1507	PMC11635641

Number	Publication	Protocol Number	PMCID
185	Walters MC, Eapen M, Liu Y, El Rassi F, Waller EK, Levine JE, Strouse JJ, Antin JH, Parikh SH, Bakshi N, Dampier CD, Jaroscak JJ, Bergmann S, Wong TE, Kota VK, Pace BS, Lekakis LJ, Lulla PD, Nickel R, Kasow KA, Popat UR, Smith WR, Yu LC, DiFronzo NL, Geller NL, Kamani N, Klings ES, Hassell K, Mendizabal AM, Sullivan K, Neuberg DS, Krishnamurti L. Hematopoietic cell transplant compared with standard care in adolescents and young adults with sickle cell disease. Blood Advances. 2025 Mar 11;9(5):955-965. Epub 2024 Oct 29.	BMT CTN 1503 PRIMARY MANUSCRIPT	PMC11907447
186	Kaur M, Horowitz MM, Mendizabal A, Chen M, Foley A, Auletta JJ, Devine S, D'Souza A. Representativeness of Blood and Marrow Transplant Clinical Trials Network (BMT CTN) trial participants. Transplantation and Cellular Therapy. 2025 Jan;31(1):49-57. doi: 10.1016/j.jtct.2024.10.014. Epub 2024 Nov 1.	Network Publication	PMC11735273
187	Martens MJ, Lian Q, Geller NL, Leifer ES, Logan BR. Sequential monitoring of time-to-event safety endpoints in clinical trials. Clinical Trials. 2025 Jun;22(3):267-278. doi: 10.1177/17407745241304119. Epub 2024 Dec 29.	BMT CTN 1204	PMC12096354
2025			
188	Holtan SG, Bolaños-Meade J, Al Malki MM, Wu J, Kitko CL, Reshef R, Rezvani AR, Shaffer BC, Solh MM, Yao JM, Runaas L, Elmariah H, Larkin KT, El Jurdi N, Gooptu M, Loren AW, Hall AC, Alousi AM, Jamy O, Clark W, Kean L, Bhatt AS, Perales MA, Applegate K, Efebera YA, Leifer E, Jones RJ, Horowitz MM, Mattila D, Saber W, Hamadani M, Martens MJ. Improved patient-reported outcomes with post-transplant cyclophosphamide: A quality-of-life evaluation and 2-year outcomes of BMT CTN 1703. Journal of Clinical Oncology. 2025 Mar 10;43(8):912-918. doi: 10.1200/JCO.24.00921. Epub 2025 Jan 3.	BMT CTN 1703	PMC12124660
189	Levis MJ, Hamadani M, Logan BR, Jones RJ, Singh AK, Litzow MR, Wingard JR, Papadopoulos EB, Perl AE, Soiffer RJ, Ustun C, Ueda Oshima M, Uy GL, Waller EK, Vasu S, Solh MM, Mishra A, Muffly L, Kim HJ, Stelljes M, Najima Y, Onozawa M, Thomson KJ, Nagler A, Wei AH, Marcucci G, Chen C, Hasabou N, Rosales M, Hill JE, Gill SC, Nuthethi R, King D, Mendizabal AM, Devine SM, Horowitz MM, Chen YB. Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML. Blood. 2025 May 8;145(19):2138-2148. doi: 10.1182/blood.2024025154.	BMT CTN 1506	PMC12105721

Number	Publication	Protocol Number	PMCID
190	Khanal M, Logan BR, Banerjee A, Fang X, Ahn KW. A Commensurate prior model with random effects for survival and competing risk outcomes to accommodate historical controls. <i>Pharmaceutical Statistics</i> . 2025 Jan 23; 24(1):e2464. doi: 10.1002/pst.2464.	BMT CTN 0901 and 1102	PMC12147052
191	Banerjee R, Fritz AR, Akhtar OS, Freeman CL, Cowan AJ, Shah N, Landau HJ, Kumar SK, Vogl DT, Efebera YA, McCarthy PL, Vesole DH, Mendizabal A, Krishnan AY, Somlo G, Stadtmauer EA, Pasquini MC. Urine-free response criteria predict progression-free survival in multiple myeloma: A post hoc analysis of BMT CTN 0702. <i>Leukemia</i> . 2025 Apr;39(4):1001-1004. doi: 10.1038/s41375-025-02534-5. Epub 2025 Feb 24.	BMT CTN 01702	PMC11978488
192	Kassim AA, Walters MC, Eapen M, Smith M, Logan BR, Solh M, McKinney C, Nieder M, Ross M, Kent M, Abusin GA, Mallhi K, Silva JG, Shaughnessy P, Kanter J, Haines H, Farah R, Khaled YA, Ritzau N, Mendizabal A, Abraham A, Bollard C, Cooke K, de la Fuente J, Hanna R, Horowitz MM, Jordan LC, Bakshi N, Krishnamurti L, Leifer E, Mahadeo KM, Shenoy S, Jones RJ, DeBaun MR, Brodsky RA. Haploidentical bone marrow transplantation for sickle cell disease. <i>NEJM Evidence</i> . 2025 Mar; 4(3):EVIDoa2400192. doi: 10.1056/EVIDoa2400192. Epub 2025 Feb 25.	BMT CTN 1507	PMC11932095
193	Gadalla SM, Katki HA, Lai TP, Auer PL, Dagnall CL, Bupp C, Hutchinson AA, Anderson JJ, Mendez KJW, Spellman SR, Stewart V, Savage SA, Lee SJ, Levine JE, Saber W, Aviv A. Donor telomeres and their magnitude of shortening post-allogeneic haematopoietic cell transplant impact survival for patients with early-stage leukaemia or myelodysplastic syndrome. <i>EBioMedicine</i> . 2025 Mar 8; 114:105641. doi: 10.1016/j.ebiom.2025.105641. Epub 2025 Mar 8.	BMT CTN 1202	PMC11930427
194	Sorrer ML, Saber W, Logan BR, Geller NL, Bellach A, Kou J, Wood WA, McCarty J, Knight TG, Runaas L, Johnston LJ, Walston JD, Nakamura R, Jarrett L, Mishra A, Uberti J, Dahi PB, Saultz JN, McCurdy SR, Morris LE, Imus P, Hogan WJ, Nadiminti KVG, Bhatt VR, Olin RL, Maakaron J, Sobecks RM, Wall SA, Mattila D, Protz B, Devine SM, Horowitz MM, Artz AS. Novel composite health assessment risk model for older allogeneic transplant recipients: BMT-CTN 1704. <i>Blood Advances</i> . 2025 Mar 18: bloodadvances.2025015793. doi: 10.1182/bloodadvances.2025015793. Epub ahead of print.	BMT CTN 1704	PMID: 40101246 (PMCID – In Process)

Number	Publication	Protocol Number	PMCID
195	Su CT, Saber W, Bansal A, Li L, Nakamura R, Cutler C, Roth JA, Wright W, Steuten L, Ramsey SD. Out-of-pocket expenditures and financial hardship among patients with myelodysplastic syndrome undergoing allogeneic transplant or hypomethylating agent / supportive care (BMT CTN 1102). Transplantation & Cellular Therapy. 2025 May 2:S2666-6367(25)01154-6. doi: 10.1016/j.jtct.2025.04.015. Epub ahead of print.	BMT CTN 1102	PMID: 40320146 (PMCID – In Process)
196	Wirbel J, Andermann TM, Brooks EF, Evans L, Groth A, Dvorak M, Chakraborty M, Palushaj B, Reynolds GZM, Porter IE, Al Malki M, Rezvani A, Gooptu M, Elmariah H, Runaas L, Fei T, Martens MJ, Bolaños-Meade J, Hamadani M, Holtan S, Jenq R, Peled JU, Horowitz MM, Poston KL, Saber W, Kean LS, Perales MA, Bhatt AS. Accurate prediction of absolute prokaryotic abundance from DNA concentration. Cell Reports Methods. 2025 May 19;5(5):101030. doi: 10.1016/j.crmeth.2025.101030. Epub 2025 Apr 28.	BMT CTN 1801	PMC12146642
197	Abedin SM, Martens MJ, Bolaños-Meade J, Al Malki MM, Lian Q, Runaas L, Elmariah H, Gooptu M, Larkin K, Shaffer BC, Loren AW, Solh MM, Alousi AM, Jamy O, Perales MA, Rezvani AR, Bhatt AS, El Jurdi N, Yao JM, Applegate K, Kean LS, Efebera YA, Reshef R, Clark WB, Leifer E, Saber W, Horowitz MM, Jones RJ, Holtan SG, Hamadani M. Impact of post-transplant cyclophosphamide-based GVHD prophylaxis in patients 70 years and older: An update from BMT CTN 1703. Blood Advances. 2025 Apr 30:bloodadvances.2025015964. doi: 10.1182/bloodadvances.2025015964. Epub ahead of print.	BMT CTN 1703	PMID: 40305657 (PMCID – In Process)